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Macrophages readily change their phenotype in response to exogenous stimuli. In 
this work, macrophages were stimulated under a variety of experimental conditions, and 
phenotypic alterations were correlated with changes in gene expression. We identified 
three transcriptionally related populations of macrophages with immunoregulatory 
activity. They were generated by stimulating cells with lipopolysaccharide (LPS), a toll 
like receptor (TLR) ligand, in the presence of three different “reprogramming” signals; 
high density immune complexes (IC), prostaglandin E2 (PGE2), or adenosine (Ado). All 
three of these cell populations produced high levels of transcripts for IL-10, as well as 
growth and angiogenic factors. They also secreted reduced levels of inflammatory 
cytokines IL-1, IL-6, and IL-12. These three activated macrophages could partially rescue 
mice from lethal endotoxemia, and therefore we consider each to have immunoregulatory 
activity. This immunoregulatory activity occurred equally well in macrophages from stat6-
deficient mice. The lack of STAT6 did not affect macrophages’ ability to reciprocally 
change cytokine production or to rescue mice from lethal endotoxemia. Furthermore, 
macrophages treated with IL-4 do not exhibit the immunoregulatory phenotype and 
  
associated transcriptional alterations. This work demonstrates that there are multiple ways 
to generate macrophages with immunoregulatory activity. These Regulatory macrophages 
(R-M) are transcriptionally and functionally related, and quite distinct from macrophages 
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Chapter 1: Introduction 
1.1 The Innate Immune System 
The innate immune system is an evolutionarily old defense strategy, often referred 
to as an organism’s first line of defense against pathogens. This system has evolved over 
millennia and can be broken down into three major categories. The first and most primitive 
way of deterring pathogens was the formation of physical barriers. The development of 
stratified epithelial layers that contain keratin provided protection against abrasions and 
makes it difficult for pathogens to enter the body. Additionally, the secretion of mucin 
helped to protect vulnerable internal membranes. The formation of a thick mucus layer 
made it difficult for pathogens to make contact with the epithelium. These barriers provided 
protection against the entry of pathogens, but could not protect the host if a pathogen made 
it into the body. 
The development of non-specific, antimicrobial molecules added a new form of 
protection. This second method included the release of complement proteins into the blood, 
gastric acid into the stomach, and lysozyme into tears. These secretions made the body a 
hostile environment for many pathogens. Complement proteins form an important arm of 
the innate immune response and provide several important antimicrobial functions 
including opsonization, agglutination and lysis1,2. Complement mediated responses 





There are three different pathways of complement activation. The first two ways to 
initiate complement activation is through the classical and lectin pathways1,2. The classical 
pathway is initiated by the C1 complex, comprised of C1q, C1r and C1s proteins, upon its 
association with antigen bound IgG or IgM antibodies. The lectin pathway relies on 
mannose-binding lectin which has the ability to directly bind to mannose residues on 
bacteria1,2. Regardless of how this pathway is initiated, the next step is the activation of 
complement proteins C2 and C4, which combine to activate C3. The third pathway of 
complement activation is referred to as the alternative pathway. This pathway relies on the 
constant low level hydrolysis of C3 proteins and the association of factor B. These two 
proteins function to convert a second molecule of C3 into its active form. The classical 
pathway, alternative pathway and the lectin pathway all converge at this point to facilitate 
the activation of C5 and the membrane attack complex. This membrane attack complex or 
MAC, inserts itself into the membrane of gram negative bacteria forming a pore and 
ultimately lysing the bacteria. The protective role of complement is well-described in 
bacterial infections causing sepsis3,4. Deficiencies in complement components can be 
attributed to a wide range of disease manifestations. Failure to initiate complement can lead 
to recurring bacterial infections, in particular, infections by bacteria in the genus Neisseria4. 
Additionally, changes in the level of complement proteins/factors have been associated 
with a wide range of human diseases including Alzheimer’s disease and systemic lupus 
erythematosus5,6. 
The cellular component forms the most important arm of the innate immune system. 





Additionally, it is also comprised of mononuclear phagocytes, which includes monocytes, 
macrophages and dendritic cells. Each of these cells are different in their structure and 
function, with each being specialized towards the various pathogens they combat. These 
cells have germline encoded receptors that allow them to recognize molecular patterns 
primarily associated with pathogens7. They all release cytokines that attract and activate 
immune cells to the sites of infections. Even though it is rare, defects in receptor signaling 
pathways can severely affect the function of innate immune cells7. These individuals often 
have recurring infections by pyogenic bacteria including members of Staphylococcus, 
Streptococcus and Pseudomonas families8. The combination of these three components 
resulted in the formation of the innate immune system. 
1.2 Cells of the Myeloid Lineage 
1.2.1 Granulocytes 
Granulocytes are comprised of neutrophils, eosinophils, basophils and mast cells. 
The circulating amounts are highly variable from person to person and are known to change 
drastically in cases of infection. Neutrophils make up the largest percentage and can range 
from 60-70% of the total circulating white blood cells9. Neutrophils have short lifespans 
and can only survive for a few hours to a few days10. These cells exhibit a high level of 
motility, and can rapidly leave the blood to enter sites of infections9,11. This cellular 
migration is mediated by chemical, cytokine and chemokine gradients that form during 





release of IL-8 and other chemokines by activated neutrophils helps to recruit immune cells 
into infected tissues11. 
Neutrophils, like many of our immune cells, have a diverse array of surface 
receptors for the detection of pathogens. They have complement receptors that help to 
identify bacteria marked by activated complement. They have Fc receptors that aid in the 
internalization of antibodies binding to bacteria12. Most importantly, they have a wide array 
of toll like receptors (TLRs) that recognize pathogen associated molecular patterns 
(PAMPs)12. PAMPs include lipopolysaccharides and lipoteichoic acids that make up 
bacterial membranes, as well as bacterial DNA. Neutrophils internalize bacteria and kill 
them through exposure to reactive oxygen species that are generated by NADPH oxidase9. 
They also release granules that contain myeloperoxidases, hydrolytic enzymes and 
lactoferrins9. These granules function to kill bacteria though the production of oxygen 
radicals and the digestion of structural proteins. Additionally, evidence has shown that 
neutrophils release extracellular traps that are composed of DNA and proteases that are 
capable of trapping and killing bacteria13. In addition to these anti-microbial responses, 
they also release inflammatory cytokines such as IL-1, IL-6, and TNF-. These 
inflammatory cytokines are responsible for changes in the vascular epithelium permeability 
and the generation of fevers14.  
The eosinophil represents a much smaller portion of circulating white blood cells 
than the neutrophils, with around 3-6% considered average15. They are longer-lived than 
neutrophils with a lifespan of about two weeks15. While neutrophils specialize in 





some anti-viral and allergic responses16,17. They are most often associated with helminthic 
infections and have been shown to be important in their clearance18. They are attracted to 
the site of infection through various chemokines including CCL11 (eotaxin-1) and CCL24 
(eotaxin-2)17. Eosinophils have been associated with anti-viral responses because of their 
production of eosinophil-derived neurotoxins and cationic proteins which exhibit RNase 
activities17,19. They have been associated with the release of pro-inflammatory cytokines, 
IL-5, IL-12 and TNF-16,17. 
The basophil represents the lowest percentage of the circulating immune cells with 
less than 1% being considered normal20. Basophils have lifespans similar to neutrophils 
and have been reported to live only a few days20. They express high levels of FcRI, which 
when cross linked, causes the release of large amounts of leukotrienes and histamine which 
help to promote allergic responses21. Basophils and mast cells were often thought of as 
being related cell populations. The main visible difference was that basophils were found 
in the blood while mast cells were associated with tissue20. New evidence has revealed that 
basophils release IL-4 and IL-13 after the cross linking of their FcRIs, while these 
cytokines have not been associated with mast cell degranulation22.  
1.2.2 Mononuclear Phagocytes 
Mononuclear phagocytes are comprised of monocytes, dendritic cells and 
macrophages. These three cell populations all have similar characteristics, but one of their 
most important characteristics is their ability to function as antigen presenting cells (APCs). 





adaptive immunity. When a mononuclear phagocyte internalizes a pathogen, antigenic 
fragments are processed and displayed on the membrane in the context of major 
histocompatibility complex class II (MHC class II) and co-stimulatory molecules CD80 
and CD86. In addition, they secrete cytokines that attract the cells of the adaptive immune 
system, T cells and B cells. 
Monocytes in blood make up to 10% of the circulating leukocytes23. Monocytes 
were long-thought to be an intermediate between bone marrow precursors and 
macrophages. However, recent studies have identified specific effector functions 
associated with these cells23. Monocytes can be divided into two primary subsets based on 
phenotype and function24,25. The CD14++CD16− classical human monocytes or 
intermediate CD14++CD16+ monocytes correspond to mouse GR1+/Ly6Chigh inflammatory 
monocytes which have a phenotype of CCR2+Cx3CR1low. The non-classical 
CD14dimCD16+ human monocytes correspond to the GR1−/Ly6Clow mouse monocytes that 
are CCR2− and express high amounts of Cx3CR1. GR1+/Ly6Chigh monocytes and their 
human CD14++CD16− or CD14++CD16+ counterparts are rapidly recruited to sites of 
infection/injury and have the potential to differentiate into either inflammatory 
macrophages or monocyte-derived DC 24,25. They efficiently produce inflammatory 
mediators such as TNF-α, nitric oxide, and reactive oxygen species. These inflammatory 
monocytes play a critical role in protection against several pathogens as demonstrated with 
the mice models of infection for Listeria, Mycobacterium, and herpes simplex virus26-28. 
Human CD14dimCD16+ non-classical monocytes and their mouse Ly6Clow equivalents 





also been shown to promote wound healing and angiogenesis in models of atherosclerosis 
and cardiac infarction29-31. 
Dendritic cells (DCs) induce and regulate adaptive immunity against pathogens, 
and tolerance against self-antigens and commensal microorganisms. Dendritic cells reside 
in the periphery during their immature state, where they recognize and capture antigens. 
Upon appropriate stimulation, DCs migrate to lymphoid organs where they present the 
processed antigens to T cells in the context of MHC class I or II32. DCs can either be 
tolerogenic, which happens when they encounter a self-antigen or a tolerogenic signal such 
as -catenin of E-cadherin33. They can also be inflammatory in the presence of microbial 
products or pro-inflammatory cytokines. Inflammation leads to the maturation of DCs 
associated with an enhanced ability to initiate T cell responses through surface upregulation 
of MHC and co-stimulatory molecules. DCs can be classified into two subsets (a) 
plasmacytoid DCs (pDCs) and (b) conventional/myeloid DCs (mDCs)25,34. The pDCs play 
a crucial role against viral infection by producing vast amounts of type I interferon in 
response to the ligation of TLR7 and TLR9 or intracellular sensor triggering35. Human 
mDCs can be divided into two main subsets based on the surface markers BDCA-1/CD1c 
or BDCA-3/CD141. BDCA-1+ mDCs produce high levels of IL-12 upon stimulation, a 
cytokine essential to inducing Th1 response and cross-priming of CD8+ T cells36. There is 
only limited data available on the functions and specializations of these DC subsets.  
The macrophage can be found in almost every tissue of the body and plays an 
important role in maintaining tissue homeostatsis. Kupffer cells, osteoclasts, and microglial 





respectively. All of these cells have taken on unique functions that give them all specific 
phenotypes; Splenic red-pulp macrophages are required to take up senescent red blood cells 
and specifically utilize the transcription factor SPI-C to transcribe the genes necessary for 
iron uptake37. Osteoclasts maintain ionic balance, alveolar macrophages in the lungs 
initiate anti-microbial responses, cardiac macrophages provide necessary signals for 
angiogenesis and neonatal heart regeneration, and microglial macrophages in the brain 
mediate several functions such as the repair of neural tissue and synaptic stripping38. These 
are just a few examples of how macrophages play important roles in the maintenance of 
tissue homeostasis. 
An important role of macrophages is to initiate an immune response to pathogens 
and foreign antigens. These cells express a wide array of surface receptors that recognize 
pathogen associated molecular patterns (PAMPs). Some of these pattern recognition 
receptors are toll-like receptors, C-type lectin receptors, NOD like receptors and RIG-I like 
receptors39,40. These receptors are specialized for the motifs they recognize. For example, 
there are 13 TLRs in total, each recognizing a particular motif; TLR2 senses peptidoglycan 
from gram positive bacteria, TLR4 recognizes LPS from gram negative bacteria, TLR9 
detects CpG rich DNA and so on. Signaling through TLRs initiates two different pathways 
(a) MyD88 dependent pathway and (b) TRIF dependent pathway41,42. When respective 
ligands bind to TLR (except TLR3), MyD88 signaling is initiated, ultimately leading to the 
activation of NF-B and MAP kinases. Translocation of NF-B into the nucleus and 
binding to specific sites on the DNA initiates transcription of inflammatory genes such as 





sometimes, LPS to TLR4 initiates the activation of TRIF which in turn activates interferon 
regulated factor 3 (IRF3) or NF-B. IRF3 activates type I interferon production and 
signaling. Unlike signaling through other TLRs, TLR3 signaling occurs mostly in DCs and 
not in macrophages. Thus sensing of pathogens in macrophages through these pattern 
recognition receptors initiate inflammatory responses that in turn lead to the amplification 
of the adaptive immune response. Another important receptor on the macrophage surface 
is the Fc receptors that recognize the Fc portion of the antibodies. This receptor helps 
macrophage to identify antibody-coated antigens and to phagocytize them. Soluble 
antigens when bound with antibodies form immune complexes (IC) that trigger 
complement activation. This leads to opsonization and the subsequent phagocytosis by 
macrophages.  
Throughout the years, discoveries have helped us to rethink the role of macrophages 
in the body. It is now understood that macrophages have several roles far beyond 
phagocytosis and that macrophages exist in several phenotypic forms. Accumulating 
knowledge suggests that different macrophage activation states are associated with the non-
stereotypical functions of macrophages, including immune regulation, maintenance of 
tissue homeostasis, and wound healing. Understanding the correlations of phenotypic 
functions is important for classifying the macrophages and for redefining the various 





1.3 Classification Systems of Macrophages 
1.3.1 Classical Activation (M1)  
The Classically Activated macrophage was the first phenotypic alternation of 
macrophages to be described, and it has been the most extensively studied. The term 
macrophage activation was introduced by Mackaness in the 1960s in an infection context 
to describe the antigen-dependent, but non-specific, microbicidal activity of macrophages 
toward BCG (Bacillus Calmette-Guerin) and Listeria upon secondary exposure to the 
pathogens43. The term, Classically Activated macrophages, is now generally reserved to 
cells primed with IFN- and stimulated with bacterial products, such as LPS, or the 
cytokine TNF- which is produced in response to bacterial products. The term M1-
macrophages has developed to describe macrophages that exhibit generalized 
inflammatory responses regardless of the stimuli used for generating them. The three most 
common and prototypical inflammatory stimuli were TNF-, TLR ligands (with or without 
IFN-) and GM-CSF44,45. Other stimuli include inflammatory cytokines such as IL-1 and 
IL-6. Regardless of the stimuli, these M1 macrophages generate large amounts of 
inflammatory cytokines including IL-1, IL-6, TNF-, IL-12 and IL-2345-47 and chemokines 
like CCL2, CCL3, CCL4, CCL5, CXCL9, CXCL10, and CXCL1145. In addition, these 
cells produce reactive oxygen and nitrogen intermediates that are capable of killing 
internalized pathogens45,48. These macrophages also express high levels of co-stimulatory 
molecules CD80/CD86 and MHC class II which facilitate their interaction with T cells, 





 There are multiple signaling pathways that are responsible for the generation of 
Classically Activated macrophages. The presence of IFN- causes an increase in STAT1 
and IRF1 signaling45,49. TLR ligation leads to MyD88 signaling pathways which activate 
various MAP and IB kinases with the end result being AP-1 and NF-B translocation into 
the nucleus44,45 (Illustration 1). The pro-inflammatory responses generated by these 
signaling pathways are important in macrophage mediated clearance of intracellular 
pathogens like Leishmania40 and bacteria like Listeria45,50. Despite their protective role 
against infections, overt signaling from these macrophages can result in 
immunopathologies resulting in unnecessary destruction of cells and tissues. 
1.3.2 Alternative Activation (M2a) 
The discovery that IL-4 and IL-13 caused murine macrophages to increase mannose 
receptor expression and to reduce their production of pro-inflammatory cytokine, led Stein 
and colleagues to propose an alternative activation phenotype51. This activation state was 
different from IFN-γ activation but far from deactivation51,52. This activation state was 
termed Alternatively Activated or M2a macrophages40,53. These macrophages failed to 
induce inflammatory cytokines but displayed increased expression of Ym1, Fizz1, Arg-1 
and mannose receptors45,54. These proteins have been associated with tissue remodeling 
and in parasitic infections53. The chemokines CCL17, CCL22, and CCL24 have also been 
reported as markers for M2 activation in macrophages46. These cells fail to upregulate co-
stimulatory molecules CD80 and CD86 and show low expression of MHC class II44. The 
















with Th2 immune responses53,55. 
As mentioned before these Alternatively Activated macrophages can be generated 
by stimulation with IL-4 or IL-13. Both of these cytokines involve signaling through the 
STAT645,53 as opposed to the STAT1 mediated signaling pathways that are activated in 
Classically Activated macrophages56,57 (Illustration 2). While Classically Activated 
macrophages express iNOS and thus produce large amounts of nitric oxide, Alternatively 
Activated macrophages express arginase and produce urea44. AA-M have been implicated 
in protection against helminth and parasitic infections55. The molecules secreted by these 
macrophages have important roles in wound healing due to their anti-inflammatory, 
fibrotic, proliferative, and angiogenic activities58. Despite their protective role, these 
macrophages have been associated in several pathologies such as allergy and asthma. 
1.3.3 M1/M2 Classification 
Mills and colleagues, while investigating the arginine metabolism of macrophages 
in mouse strains with Th1 and Th2 backgrounds, found that macrophages from these mice 
differed qualitatively in their ability to respond to the classic stimuli IFN-γ or 
lipopolysaccharide (LPS). Hence they introduced a M1/M2 classification systems to mirror 
the Th1/Th2 classification system of T cells by Mossman and Coffmann59,60. Mills and 
colleagues went further and proposed that the M1/M2 dichotomy was an intrinsic property 
of macrophages associated with transitions from inflammation to healing. This would 
occur in the absence of an adaptive immune response and arose early in evolution60. Later 

















IFN-/LPS treated macrophages and the non-inflammatory IL-4 treated macrophages. The 
failure of AA-M to produce nitric oxide has been attributed to their induction of Arginase-
1, which converts arginine to ornithine 44,48. Consequently, Arg-1 has been used as a 
biomarker to identify AA-M, and several groups have mistakenly identified AA-M in 
tissue based on their expression of Arg-1. Subsequent demonstrations that multiple 
stimulated macrophages could produce Arg-1 revealed a fundamental confusion in the field 
that all non-M1 macrophages are AA-M61. This confusion lead to the further classification 
of M2 macrophages into further subsets. At least three different subtypes of M2 
macrophages have been defined: M2a macrophages that represent the conventional 
Alternatively Activated macrophages generated by addition of IL-4 or IL-13, M2b 
(immune complexes in combination with IL-1 or LPS) and M2c (IL-10, TGF- or 
glucocorticoids)62. Stimulation with G-CSF is a latest addition to these subtypes. The over-
simplification of classifying macrophages other than Classically Activated macrophages 
as M2 macrophages has led to substantial confusion in the field of macrophage biology. 
First, researchers in the field get confused about which terminology to use and which 
markers define the subset of macrophages. Secondly, often the M1 and M2 macrophage 
coexist rather than being a distinct population and the occurrence of these subtypes is 
dependent on the activation signals in the microenvironment. Finally, it provides a false 
impression that a macrophage can exist only in one of the two states. This grey area in 
macrophage phenotypes and functions calls for a revision of macrophage nomenclature in 





1.3.4 Regulatory Activation (M2b) 
The identification of macrophages with regulatory functions emerged from an 
unexpected observation that was made by stimulating macrophages in the presence of high-
density immune complexes. This resulted in a unique cytokine response that was markedly 
different from that of Classically Activated macrophages63. Previous members of the 
Mosser lab observed that a combination of a TLR ligand with immune complexes resulted 
in macrophages that produce high levels of the anti-inflammatory cytokine IL-10 and little 
to no detectable IL-1244. This phenotype was in stark contrast to Classically Activated 
macrophages that produce high levels of IL-12 but relatively low levels of IL-10. 
Interestingly, the Regulatory macrophage retained the capability to induce IL-10 even 
when pretreated with IFN-. Additionally, stimulating macrophages with a TLR ligand 
and a secondary signals such as apoptotic bodies, prostaglandins or adenosine was capable 
of generated macrophages with an immunoregulatory phenotype40. The chemokine CCL1 
was upregulated in Regulatory macrophages(R-M)46 and similar to classical activation, 
the co-stimulatory molecules CD80/CD86 and MHC class II were also upregulated44. 
Interestingly, the high level of IL-10 production by R-M leads to Th2 biasing in T cells44. 
These immunoregulatory macrophages not only differed from Classically Activated 
macrophages but also from AA-M. While the AA-M participate in wound healing, the 
Regulatory macrophages appeared to limit tissue damage and did not appear to actively 





The addition of a reprogramming second signal is central to the R-M phenotype. 
The signals reduce pro-inflammatory IL-12 production and increase anti-inflammatory IL-
10 levels64,65. The binding of these secondary signals to their receptors causes activation of 
various signaling pathways. In the case of immune complex binding, there is activation of 
the Fc receptors which signal through Syk kinase66. The activation of Syk in turn activates 
high levels of the Map kinase, ERK67,68 (Illustration 3). The activation of ERK results in 
the phosphorylation of histones associated with the il-10 promoter, which makes the 
promoter more accessible to the transcription factors that induce il-10 gene expression. The 
binding of adenosine and prostaglandin E2 to G-protein coupled receptors causes increases 
in intracellular cAMP levels69-71. The increased cAMP level leads to activation of protein 
kinase A and subsequently to CREB transcription factor activation (Illustration 3). 
Additionally, G protein coupled receptor signaling leads to Ras activation with the end 
result being increased ERK activation. While these signaling pathways arise from different 
signaling proteins, they result in the induction of IL-10. Thus, although R-M shares some 

















Despite the advances we made in understanding of these Regulatory macrophages, 
there are still many unknown aspects of these cells. The in vivo significance of this 
population in the context of a disease or an infection, the in vivo generation or occurrence 
of these cells and the markers that define regulatory activation are still poorly understood 
topics. This study aims at identifying stable markers to define R-M and their in vivo 
significance in an infection model. 
1.3.5 Color Wheel  
As macrophage activation has become better understood, the need for a broader 
classification system became apparent. The linear M1/M2 was not capable of 
accommodating the macrophages with immunoregulatory abilities or those that arose from 
multiple cellular stimulations. The understanding that macrophages activation was no 
longer linear, led to our proposed color wheel model to be adopted (Illustration 4)40. This 
model allows the accommodation of the three distinct macrophage subpopulations: the 
Classically Activated macrophages/M1-M, the Alternatively Activated macrophages, and 
the Regulatory macrophages. Additionally, this color wheel scheme accounts for the 
existence of hybrid activation states that share phenotypic traits associated with multiple 
activation states. This model has helped us to understand the plasticity of macrophages, 
which the linear model of macrophage activation was unable to explain. Further, this model 
can accommodate the yet to be defined shades of activation resulting in a spectrum of 











Illustration 4: Color Wheel. The three major macrophage subtypes and some of the 
biochemical and physiological properties of each. ↑↓ designated high or low expression in 
this subpopulation, related to the other three: ++, +, –, designates relative activity from 
high (++) to absent (–). Adapted from the European Journal of Immunology, “Regulatory 







Chapter 2: Tools for Studying Macrophages 
2.1 Studying at the DNA Level 
2.1.1 Background 
All gene expression starts with the transcription of DNA into RNA. The sequences 
that make up the promoter region and the accessibility of these sites to transcriptions factors 
determine whether or not a gene will be expressed. The availability of genomic sequences 
has provided a new tool in studying gene expression. It is possible to analyze promoter 
sequences in an attempt to predict transcription factor binding sites72. Additionally, 
conserved patterns like start codons and splice junctions, can help identify previously 
undiscovered genes. The organization of DNA into nucleosomes provides a second level 
of regulation. The nucleosomes is a histone-DNA complex that undergoes structural 
rearrangements to facilitate or inhibit transcription factor binding. The histone-histone or 
histone-DNA interactions together with the histone modifications elicit effects such as gene 
activation or gene repression73,74. The type of histone subunits, such as H1, H2A, H2B, H3 
or H4 or their subtypes can have a direct effect on how they will be modified following 
signaling cascade activation75. Some of these modification are long-lived and can be used 
as indicators of differentiation states of various cell types. The stable differentiation of T 






2.1.2 Experimental Applications 
The regulation of gene expression at the level of DNA was vital for the 
understanding of the “reprogramming signal” and the induction of IL-10 in Regulatory 
macrophages. Work by Lucas et al from the Mosser lab showed that ERK kinase activation 
following FcR ligation in R-M leads to chromatin modifications at the IL-10 locus67,77. 
Through chromatin immunoprecipitation assays (CHIP), the authors demonstrated that 
activation of ERK leads to the serine phosphorylation on histone H3 at the il-10 gene, 
making the promoter more accessible to transcription factors67. Further work by Zhang et 
al., in the Mosser lab used CHIP assays and phosphorylation studies to explore the kinetics 
of histone modification. and showed that the histone phosphorylation and not acetylation 
was the proximal event to IL-10 induction77. Cao et al. from the Mosser lab utilized 
electrophoretic mobility shift assays and reporter assays to show that NF-B1 (p50) 
homodimers can be transcriptional activators of IL-10.78. These molecular methods were 
used by previous lab members to demonstrate the epigenetic and transcriptional 
modifications associated with Regulatory macrophages.  
2.2 Studying at the RNA Level 
2.2.1 Background 
Studying the levels and kinetics of mRNA expression can help us to predict how 
the protein signature of these cells will be affected. Gene expression profiling assays have 
been a valuable tool in studying alterations in mRNA expression. The first high throughput 





relied on the hybridization of labeled RNA to gene specific probes adhered to a substrate. 
The comparative analysis of label intensities allowed researchers to quantify the relative 
expression level of numerous genes in multiple samples79. 
Recent advances in nucleotide sequencing have allowed for the development of a 
new technology known as RNA-seq (RNA sequencing) or WTSS (Whole Transcriptome 
Shotgun Sequencing). RNA-seq has revolutionized the way in which molecular biology 
research can be conducted. Researchers can now isolate total RNA from a cell and identify 
the origin of these transcripts through sequencing. RNA-seq provides wider coverage of 
the studied genes and provides a snapshot of the RNA expression in the studied cell types. 
RNA-seq technology helps us to identify previously unknown genes, micro RNAs and 
splice variants. All of these advances have made RNA-seq a powerful tool for studying 
gene expression in macrophages80. 
Examining relative changes in RNA expression was made possible by real time 
PCR. A real time polymerase chain reaction is used to amplify and simultaneously detect 
or quantify a targeted cDNA molecule that have been synthesized from a RNA sample. 
Two common methods of quantitative real time PCR (qRT-PCR) are: (1) relative 
quantification that uses non-specific fluorescent dyes that intercalate with any double-
stranded DNA, and (2) absolute quantification, which uses sequence-specific probes along 





2.2.2 Experimental Applications  
To study the differences in the gene expression profile between CA-M and R-M, 
this lab previously utilized microarray analyses. The results of that data helped to first 
identify tnfsf14 and hb-egf genes to be associated with regulatory activation44,82. To identify 
genes that were dependent on ERK activation, we performed microarray analysis in R-M 
pretreated with the MEK inhibitor U0126. From these unpublished results, we predicted 
that IL-33 was a MEK dependent regulatory marker in R-M. Attempts are underway to 
validate this finding. 
To further characterize R-M and the markers associated with it, we had to take a 
better approach that would provide us a wider coverage of the genes studied. Therefore, in 
the study presented in this dissertation, we performed RNA-seq analyses on M1-M (LPS 
stimulation), AA-M (IL-4 stimulation) and Regulatory macrophages obtained from two 
different stimuli LPS stimulation paired with OVA-IC or adenosine. The results obtained 
from RNA-seq were validated using the qRT-PCR assays. The result of this study is to 
follow in the Results and Discussion section of this dissertation.  
2.3 Studying at the Protein Level 
2.3.1 Background 
One of the most well established ways of characterizing macrophage activation 
states has been through the identification of secreted cytokines. The switch between IL-12 





M44. The cytokine measurements are usually obtained by Enzyme linked immunosorbent 
assay (ELISA) that utilizes a pair of antibodies targeted for each cytokine to be 
characterized. While ELISA remains the best way to quantify the protein levels, it limits 
the number of cytokines that can be examined at once. Another commonly used semi-
quantitative method is western blotting which can detect a specific protein in a given 
sample. 
 The development of high throughput methods such as protein membrane arrays 
and multiplex assays has allowed researchers to examine several proteins in a single 
experiment. The membrane array is done by measuring the amount of protein that has 
hybridized to a nitrocellulose membrane spotted with multiple antibodies. Although this 
method helps for the initial screening of the proteins, it is only a semi-quantitative method. 
Multiplex assays, on the other hand, provide a quantitative tool that enables one to quantify 
several proteins in the sample by utilizing target specific fluorochrome conjugated beads. 
Multiparametric analysis at the cellular level was made possible with the advent of flow 
cytometry. The technique allows high throughput automated analysis of various parameters 
using lasers and fluorochromes. Flow cytometry is a widely used technique especially in 
the field of immunology and other fields of biology. 
The advancements in mass spectrophotometry have enabled the identification of 
proteins present by analyzing their amino acid sequence composition. Researchers can 
fractionate cytosolic or membrane bound proteins and analyze their expression83. This 
technology might be limited in the ability to quantify the amounts of protein being made, 





2.3.2 Experimental Applications 
For this study, I utilized ELISA, protein membrane array, multiplex assay and flow 
cytometry. ELISA was used to assess the cytokine levels in the supernatants of the 
stimulated macrophages. Protein membrane array was used to identify the proteins that are 
differentially regulated in R-M compared to other types. Flow cytometry was used to 
check if the high mRNA expression of some of the genes identified by RNA-seq analyses 
was translated at the protein level. Finally, multiplex assay was used to quantitate 
cytokine/chemokine levels secreted by human macrophages. 
2.4 Research Objectives 
 The previous work by members of the Mosser lab has laid the groundwork for our 
understanding of how the Regulatory macrophage is generated and how these cells respond 
during activation. The research described in this dissertation focuses on several important 
aspects of regulatory activation that have been poorly described. First, I will determine if 
adenosine and prostaglandin E2 are capable of inducing regulatory activation in 
macrophages and will determine if all Regulatory macrophages have the same phenotype. 
Second, I will identify the core genes required for the immunoregulatory phenotype. This 
will serve to both identify new therapeutic targets, as well as help us to understand how the 
macrophage interacts with the immune system. Third, I will use the core genes to identify 
stable biomarkers that can be used to identify Regulatory macrophages. The ability to 
identify a macrophage’s activation state in tissue would benefit countless diagnostic and 





plays in the disease endotoxemia. Finally, I will compare the various Regulatory 
macrophages to Alternatively Activated macrophages to determine if they share 
phenotypic similarities. This research will help us to better understand the mechanisms for 
regulatory activation and provide important information that will help in the classification 





Chapter 3: Comparative Analysis of  
Activated Macrophage Populations 
3.2 Introduction 
The plasticity of macrophages allows these cells to undergo dramatic alterations in 
their phenotype in response to diverse environmental stimuli40,84-88. This phenotypic 
heterogeneity of macrophages has led to a substantial degree of confusion in the field about 
how best to name these cells. This is not simply a semantic problem. A better understanding 
of the phenotypic alterations that macrophages undergo is necessary if we eventually hope 
to manipulate immune responses at the level of macrophages. Studies on macrophage 
heterogeneity can put us in a better position to generate macrophages with a predictable 
phenotype, to deplete one set of macrophages while preserving others, or to target drugs to 
individual subpopulations of macrophages.  
The pioneering work of Gordon and colleagues in the 1990s helped to define two 
paradigmatic populations of macrophages, generally referred to as “Classical" versus 
"Alternative” but later termed M1 versus M2, or M(IFN-) versus M(IL-4)45,51,87,89. 
Exposing macrophages to IFN- and TLR ligands results in an upregulation of 
inflammatory cytokines, an increased MHC class II and co-stimulatory molecule 
expression, and the production of antimicrobial products51,90-93. Cells exposed to IL-4, in 
contrast, fail to upregulate co-stimulatory molecules and MHC class II, are poor antigen 
presenting cells, and produce negligible amounts of nitric oxide. These cells express higher 





macrophages (AA-M)51,94,95. The linear M1/M2 classification system remained the 
standard for describing macrophage activation states for nearly a decade. Gradually, 
investigators came to appreciate the limitations of this narrow classification system and 
attempted to expand the M2 classification to include macrophages that were treated with 
glucocorticoids, anti-inflammatory cytokines, extracts from tumors, apoptotic cells, 
immune complexes, or adenosine derivatives, to name a few.  
A color wheel scheme was proposed to highlight the plasticity of macrophages40,96. 
This model placed an emphasis on the dynamic nature of macrophage activation and 
proposed that macrophages can readily transition from one activation state to another. 
Therefore certain tissue resident macrophages may not express clear phenotypic 
characteristics of a single population. In this study, we examine five different macrophage 
populations from different segments of the color wheel and demonstrate that macrophages 
treated with IL-4 are transcriptionally and phenotypically distinct from three macrophage 
populations with immunoregulatory phenotypes. We also show that although these three 
immunoregulatory macrophage populations can be distinguished from each other at the 
global transcriptome level, they all share a number of characteristics that endow them with 
immunoregulatory activity, including the reduced production of inflammatory cytokines 
and the secretion of growth and angiogenic factors. Therefore we loosely group them 
together as Regulatory macrophages (R-M). We describe chemokine and cytokine 





3.3 Methods and Materials 
3.3.1 Mice 
Five-week-old BALB/c mice were purchased from Charles River (Frederick, MD). 
Mice were used at 6-10 weeks of age as a source of bone marrow to culture bone marrow 
derived macrophages (BMDM). All mice were maintained in high-efficiency particulate 
air-filtered Thoren units (Thoren Caging Systems, Hazleton, PA) at the University of 
Maryland (College Park, MD) animal facility. All procedures were reviewed and approved 
by the University of Maryland Institutional Animal Care and Use Committee. 
3.3.2 Murine Macrophage Generation 
Bone marrow derived macrophages (BMDM) were obtained by flushing the femurs 
and tibiae of BALB/C mice, and plating the cells in petri dishes containing BMM medium 
(DMEM/F12 medium with 10% fetal bovine serum, 1% glutamine, 1% 
penicillin/streptomycin and supplemented with 15% L929 cell conditioned media 
(LCCM)). Cells were grown in a 37 C incubator with 5% CO2 and fed again with 
BMM/15% LCCM on day 3. For peritoneal macrophages, female mice were sacrificed and 
their peritoneal cavity was lavaged with cold 8-10 ml of PBS (Ca2+/Mg2+ free). Cells 
obtained from 10-12 mice were pooled, washed, and suspended in DMEM/F12 medium 
supplemented with 10% FBS, glutamine, and antibiotics and plated in a 6 well plate at a 
density of 2x106 cells/ml. After overnight resting, the cells were stimulated with LPS, 
LPS+IC, LPS+adenosine, or IL-4 as indicated under the ‘Cell Culture and Stimulation’ 





from the cells using the TRIzol-chloroform method according to the manufacturer’s 
instructions. RNA-seq analyses were performed separately on three different sample sets 
obtained on different days. 
3.3.3 Human Macrophage Culture 
Peripheral blood was collected from six healthy human volunteers and the 
mononuclear cells were separated by Ficoll-Hypaque density gradient centrifugation. The 
cells were incubated in 12 well tissue culture plates in the presence of plain RPMI medium 
(Gibco, Grand Island, NY) for two hours. The non-adherent cells were removed with four 
washes of HBSS. The adhered monocytes were cultured for a week in RPMI 1640 medium 
supplemented with 10% human AB serum (Life Technologies, Grand Island, NY) in the 
presence of 1% glutamine, 1% penicillin/streptomycin, and 50 ng/ml of M-CSF 
(Peprotech, Rocky Hill, NJ). The media was replaced with fresh media after 72 hours and 
12 hours before stimulation. An additional wash to remove dead and non-adherent cells 
was carried out with HBSS before adding the fresh media for stimulation. All studies on 
human monocyte-derived macrophages were approved by the University of Maryland, 
Institutional Review Board (484966-2). 
3.3.4 Cell Culture and Stimulation 
LPS treated macrophages were generated by adding 10 ng/ml ultra-pure LPS 
(Invivogen, San Diego, CA). Regulatory macrophages were obtained by stimulating 
BMDMs in the presence of 10 ng/ml LPS and one of the following “reprogramming” 
signals: high density immune complexes generated as previously described97 by adding 1 





Warrington, PA) in a volume of 21 µl, 200 µM PGE2 (Cayman Chemical, Ann Arbor, MI), 
or 200 nM adenosine (Sigma-Aldrich, St. Louis, MO) (designated in the text as RM-IC, 
RM-PGE2 and RM-Ado, respectively). Alternatively Activated macrophages were 
generated by adding 20 ng/ml mouse IL-4 (R&D Systems, Minneapolis, MN) to 
macrophages and designated AA-M in text. For RNA isolation, 2x106 BMDM (day 7-10) 
were stimulated in six well plates for 2-6 hours as indicated in the figures. For cytokine 
analyses of cell culture supernatants, 2.5x105 BMDM were placed in 48 well plates in a 
volume of 0.5 ml and stimulated for 12-16 hours. For the membrane protein array, 2x106 
BMDM were stimulated for 12 hours in a six well plate in 1 ml of media. For the bioplex 
analyses, differentiated human macrophages were plated at a concentration of 5x105 
macrophages/ 0.5 ml in 48 well plates and supernatants were collected after 24 hours. The 
supernatants were stored at -80 C until assayed. 
3.3.5 ELISA 
IL-12/23p40 and IL-10 levels were measured from cell-culture supernatants by 
sandwich ELISA method using antibodies purchased from BD Pharmingen (San Diego, 
CA) ([IL-12p40- C15.6 and C17.8], [IL-10- JES5-2A5 and JES5-16E3]) according to 
manufacturer’s instructions. IL-1, IL-6 and human IL-12/IL-23p40 levels were measured 
using Duoset ELISA kits (R&D systems, Minneapolis, MN), following manufacturer’s 
instructions.  
ELISA was performed by coating high bind plates with 100 μl capture antibody in 





washed three times with ELISA wash buffer (PBS with 0.05% Tween20), followed by 200 
μl of blocking buffer (ELISA wash buffer + 10% FBS). After a 30 minute incubation at 
room temperature, plates were washed three times with ELISA wash buffer. Samples and 
serially diluted standards (typical diluted in RPMI with concentrations ranging from 4000 
pg/ml to 15.625 pg/ml) were incubated in the wells overnight at 4 C or at room 
temperature for 3 hours. Plates were washed three times with ELISA wash buffer, followed 
by a one hour incubation of detection antibody diluted in blocking buffer. Wells were 
washed four times with ELISA wash buffer, followed by the addition of 100 μl of diluted 
streptavidin-AP or streptavidin-HRP in blocking buffer. Wells were washed five time and 
loaded with pNPP substrate or TMB substrate solution. Plates were developed for up to 30 
minutes and HRP reactions were stopped with 0.2 M H2SO4. Optical densities were 
determined at 405 nm (pNPP substrate) or 450 nm (TMB substrate), with background 
readings taken at 595 nm.  
3.3.6 Membrane Protein Array 
Mouse cytokine antibody array membranes (Proteome Profiler Antibody ArrayTM 
(Panel A), R&D systems, Minneapolis, MN) were used to assess the relative differences of 
40 different cytokines and chemokines in the supernatants of various macrophage 
populations. The array was performed following manufacturer's instructions and the 
chemiluminescence was detected and the density was quantified using LAS-3000 Imaging 





against a positive internal control provided with the array. Stimulation details can be found 
in the ‘Cell Culture and Stimulation’ section.  
3.3.7 Bioplex Assay 
The levels of cytokines/chemokines were measured from the supernatants of human 
macrophage cultures collected after 24 hours using the human magnetic Luminex screening 
assay (R&D systems, Minneapolis, MN). A 14-plex assay was carried out for the detection 
of secreted proteins following manufacturer’s protocol. The samples were acquired in 
Magpix® and data was analyzed with the Luminex xPONENT software (Luminex 
Corporation, Austin, TX). The sample concentrations were calculated from the standard 
curves using five-parameter regression analyses. The obtained data was analyzed and 
plotted using Graphpad prism Version 6 software (Graphpad Software Inc, La Jolla, CA). 
Stimulation details can be found in the ‘Cell Culture and Stimulation’ section. 
3.3.8 RNA Isolation and cDNA Synthesis 
RNA was isolated from 2x106 cells using TRIzol according the manufacturer’s 
specifications. Complementary DNA (cDNA) was synthesized from 2 g equivalent of 
RNA using cDNA synthesis kit (Invitrogen, Grand Island, NY), according to the 
manufacturer’s instructions. Briefly, RNA was diluted up to 10.5 μl with nuclease free 
water, then 4 μl 5x cDNA buffer, 2 μl dNTP, 1 μl DTT, 1 μl RNaseOut, 1 μl Oligo dT20, 





minutes, 60 C for 60 minutes, 85 C for 5 minutes, then held at 37 C. Followed by 1 μl 
of RNaseH, an incubation at 37 C for 20 minutes and 179 µl to dilute the sample. 
3.3.9 Conventional PCR 
PCR reactions were set up by adding 2 μl of diluted cDNA, 1 μl each of sense and 
anti-sense primers (5 pmols), 8.5 μl of nuclease free water and 12.5 µl of 2x PCR master 
mix (Fermentas, Pittsburgh, PA) for each reaction. PCR was carried out with denaturation 
for 95  C for 5 minutes, DNA amplification for 30 cycles of 95 C for 40 seconds, 58 C 
for 40 seconds, 72 C for 60 seconds, with a final extension at 72 C for 7 minutes. Primers 






Table 1. Primer Pair Sequences 
Gene Accession number Primers (Amplicon Length)   
il-12p40 NM_008352 5’-AAGACGTTTATGTTGTAGAGGTGGAC-3’ (180) 
    5’-ACTGGCCAGGATCTAGAAACTCTTT-3’ 
il-10 NM_010548 5’-GACTTTAAGGGTTACTTGGGTTGC-3’ (190) 
    5’-TCTTATTTTCACAGGGGAGAAATCG-3’ 
relm NM_020509 5’-AATCCAGCTAACTATCCCTCCA-3’ (103) 
    5’-CAGTAGCAGTCATCCCAGCA-3’ 
ym1 NM_009892 5’-AGGGTAATGAGTGGGTTGGT-3’ (220)  
    5’-AGCTCCTCTCAATAAGGGCC-3’ 
il-33 NM_133775 5’-ATGGGAAGAAGCTGATGGTG-3’ (150) 
    5’-CCGAGGACTTTTTGTGAAGG-3’  
flrt3 NM_01172160 5’-TCTGGCTTATATGAGATGCTTGA-3’ (197) 
    5’-GTCATGGCAACAAAAAGTGG-3’ 
ccr1 NM_009912 5’-AAGAGCCTGAAGCAGTGGAA-3’ (204) 
    5’-CAGATTGTAGGGGGTCCAGA-3’ 
gem NM_010276 5’-TTGAAGGCTATTGGGACCAG-3’ (228) 
    5’-AACTCATGTGAACCCGAAGC-3’ 
ildr1 NM_134109 5’-CAAACTGGCCTGAGGAGAAG-3’ (164) 
    5’-AAGGCAGCTGGAACTCTTGA-3’ 
emp1 NM_010128 5’-CTCCCTTGTGGTCTTCGTGT-3’ (163) 
    5’-GCTGCTGGAGTTGAAGTTCC-3’ 
il-4i1 NM_010215 5’-AGCTTTGCAGAAGCCTTACG-3’ (152) 
    5’-TGAGTGATCGACACCACAGG-3’ 
ear11 NM_053113 5’-CAACTCCGGCCAGTCATTAT-3’ (234) 
    5’-TGACATGCAGTGCAAACAGA-3’ 
cd209e NM_130905 5’-GGAGAATGGTACTGGCTGGA-3’ (211) 
    5’-TGCAGAGAACGTCTGGTCAC-3’ 
ndrg1 NM_008681 5’-CATGAATGTGAACCCCTGTG-3’ (213) 
    5’-CTGTTGTAGGCGCTGATGAA-3’ 
klk9 NM_028660 5’-GGATCTGAGCCTTGTTCCAG-3’ (162) 
    5’-GAATCCTGCAGCATCCTCTC-3’ 
dusp14 NM_019819 5’-TGGGTGTTCGGGTTTAAGAG-3’ (204) 
    5’-GAGCTCCTACTGCACCTGCT-3’ 
hc NM_010406 5’-ACCAGATAAGCAGTGCACCA-3’ (209) 
    5’-CAGTGGCTGATGTGATCCTG-3’ 
tnfsf14 NM_019418 5’-CTGCATCAACGTCTTGGAGA-3’ (205) 
    5’-GATACGTCAAGCCCCTCAAG-3’ 





Table 1. Primer Pair Sequences (Cont.) 
Gene Accession number Primers (Amplicon Length)   
cd244 NM_018729 5’-AGTGCAAGCCTTCTGATTCC-3’ (242) 
    5’-CTGCATGACACAGGATGAGG-3’ 
lif NM_008501 5’-CTTGCTTGCTGGGTGTATGA-3’ (171) 
    5’-GATCCCAGTCCCCTTAGCTC-3’ 
xcr1 NM_011798 5’-TCATCTTCACCGTCGTGGTA-3’ (156) 
    5’-AGCAATGAGAGAAGGCCAAA-3’ 
mid1 NM_010797 5’-CCTCAGAGGACGAGTTCAGC-3’ (205)  
    5’-TACTTGGTGCCACTTTGCAG-3’ 
mospd4 NR_045438 5’-GCCTCTTCCTGTTGTTCTGC-3’ (175) 
    5’-CGGGCCATACTTCCAATAGA-3’  
gapdh NM_008084 5’-AAGGTCGGTGTGAACGGATTT-3’ (155) 







Relative quantification of RNA was done using SYBR-Green based quantitative 
real time PCR. The samples were run in Roche LightCycler® 480, in a 96 well plate. Each 
well contained 5 µl of diluted cDNA, 1 µl each of sense and anti-sense primers (5 pmol), 
5.5 µl of nuclease free water and 12.5 μl of 2x go-Taq PCR master mix (Promega, Madison, 
WI). For data analysis, the comparative threshold cycle (CT) value for gapdh was used to 
calculate relative differences. The fold induction of RNA was calculated using 2^(-ΔΔCT) 
method98. 
3.3.11 RNA-seq Data Generation and Processing 
Poly(A)-enriched cDNA libraries were generated using the Illumina TruSeq 
Sample Preparation kit (San Diego, CA). Paired end reads (100 bp) were obtained from the 
Illumina HiSeq 1500 platform. Trimmomatic99 was used to remove any remaining 
Illumina adapter sequences from reads and to trim off bases with quality scores below 20. 
Sequence quality metrics were assessed using FastQC 
[http://www.bioinformatics.babraham.ac.uk/projects/fastqc/]. Reads were aligned to the 
Mus musculus genome (v. mm10/GRCm38) obtained from the UCSC genome browser 
(http://genome.ucsc.edu) using TopHat (v 2.0.10)100. Reads were allowed to map only to 






3.3.12 Data Quality Assessment and Differential Expression Analysis 
Multiple approaches were used to evaluate replicates and to visualize sample-
sample distances, including Principal Component Analysis (PCA) and Euclidean 
distances-based hierarchical clustering. All components of the statistical pipeline, named 
cbcbSEQ, can be accessed on GitHub (https://github.com/kokrah/cbcbSEQ/). Non-
expressed and weakly expressed genes were removed prior to differential expression 
analysis and a quartile normalization scheme was applied to all samples101. Limma (a 
Bioconductor package)102 was used to conduct differential expression analyses following 
log2 data transformation and the application of the voom103 method. Experimental batch 
effects were adjusted for by including batch/experimental date as a covariate in the 
statistical model104. Differentially expressed genes were defined as genes with a 
Benjamini-Hochberg multiple-testing adjusted p value of < 0.05. 
3.3.13 Ingenuity Pathway Analysis 
Ingenuity Pathway Analysis (IPA) software105 was used to predict ‘Diseases and 
Functions’ and ‘Canonical Pathways’ associated with each macrophage population. The 
‘Diseases and Functions’ associations were determined by comparing R-M to LPS 
stimulated (M1) macrophages. LPS treated and IL-4 treated macrophages were compared 
individually to resting macrophages. Canonical pathways were determined by comparing 
stimulated conditions to resting macrophages. Genes that exhibited less than a two-fold 





3.3.14 Macrophage Metabolism 
BALB/c bone marrow derived macrophages were plated in 48 well plates in 0.5 ml 
of BMM medium at a concentration of 5x105 cells per ml. The five activated conditions 
were generated as described in the ‘Cell Culture and Stimulation’ section. At 24 hours post 
stimulation, the media were collected and glucose levels were determined by using a 
Glucose Assay Kit (Sigma-Aldrich, St. Louis, MO) per the manufacturer’s instructions. In 
the L-lactate experiment, cells were plated in a similar fashion, but the media were replaced 
with phenol red-free RPMI prior to stimulation. Cell culture supernatants were removed 8 
hours post stimulation and L-lactate production was determined using L-lactate kit I (Eton 
Biosciences, San Diego, CA) per the manufacturer’s instructions. 
3.3.15 Flow Cytometry 
Surface expression of mouse CCR1 was detected using antibodies conjugated to 
the PE fluorochrome. Antibody was purchased from R&D Systems (Minneapolis, MN) 
and the staining was carried out in FACS buffer (1x PBS + 3% FBS) for 15 minutes. 
Expression was measured at 24 hours post-stimulation. Data acquisition was carried out 
using FACSCantoTM II (BD biosciences, Franklin Lakes, New Jersey) and the analyses 
were done using FlowJo version 10. 
3.3.16 Lethal Endotoxin Challenge 
BALB/c BMDMs were plated in low bind 6 well plates and stimulated under 
various conditions. Cells were washed, pelleted at 300 g for 5 minutes, resuspended at 1 x 





Three hours after cell transplantation, mice were challenged with 10 mg/kg lethal dose of 
endotoxin (L2630, Sigma-Aldrich, St. Louis, MO). Survival of the mice was monitored 
and recorded for a week. 
3.3.17 Statistics 
Non-parametric t-tests were performed to calculate the significance of the observed 
differences. A p value of <0.05 was considered to be significant for all analyses. The data 
in the graphs represent mean ± standard error of the mean (SEM). 
3.4 Results 
3.4.1 Cytokine and Chemokine Profiles of Immunoregulatory Macrophages 
To better understand the differences between Alternatively Activated macrophages 
(AA-M) and Regulatory macrophages (R-M), cytokine and chemokine profiles of five 
different stimulation conditions were examined and compared. The macrophages studied 
included M1 macrophages (M1-M) treated with the TLR4 ligand LPS, Alternatively 
Activated macrophages that received IL-4 (AA-M), and macrophages that were 
stimulated with LPS in the presence of three different “reprogramming” stimuli: immune 
complexes (RM-IC), prostaglandin E2 (RM-PGE2), or adenosine (RM-Ado). The 
addition of these reprogramming signals to macrophages resulted in dramatic changes in 
their cytokine and chemokine expression. As expected, M1-M stimulated with LPS 
exhibited an inflammatory phenotype, secreting high IL-12/23p40, IL-1β, and IL-6 but low 








Figure 1: Cytokine secretion by Regulatory macrophages. BALB/c WT bone marrow 
derived macrophages were treated with 10 ng/ml LPS (L), a combination of LPS and 1µg 
of OVA opsonized with anti-OVA antibody (L+I), 200 nM PGE2 (L+P), 200 μM adenosine 
(L+A), or 20 ng/ml IL-4 for 16 hours. The levels of IL-10 (A), IL-12/23p40 (B), IL-1β (C) 
and IL-6 (D) were measured in their supernatants by ELISA. Error bars indicate Mean ± 








PGE2, or Ado, were substantially less inflammatory. They secreted higher levels of IL-10, 
completely suppressed the production of IL-12/23p40, and partially suppressed IL-1β and 
IL-6 secretion (Figure 1). The importance of STAT6 signaling has been demonstrated to 
be important in the IL-4 mediated alternate activation of macrophages. To test if regulatory 
functions were also dependent on STAT6, macrophages from stat6 knockout mice were 
challenged under the same stimulatory conditions. Macrophages from these mice exhibited 
a similar cytokine pattern as wild type (WT) mice when exposed to IC, PGE2 or Ado, 
producing higher levels of immunoregulatory IL-10 and reduced levels of inflammatory 
cytokines IL-12/23p40, IL-1β, and IL-6, indicating that STAT6 signaling is dispensable 
for generating macrophages with an immunoregulatory phenotype (Figure 2). In contrast 
to R-M that produced high levels of cytokines, IL-4-treated AA-M produced little or no 
detectable amounts of the studied cytokines (Figure 1). RT-PCR analyses of AA-M from 
WT mice revealed high transcription of relmα and ym194, confirming that our IL-4 
treatment had indeed generated AA-M (Figure 3). Macrophages from mice genetically 
deficient in stat6 failed to transcribe relmα and ym1 in response to IL-4, as expected (Figure 
3). This experiment helped to illustrate that the STAT6 signaling pathway that is required 
for alternative activation is dispensable in regulatory activation. 
To gain a more global understanding of the cytokine/chemokine profile of activated 
macrophages, we performed a membrane array that looked at over 40 different cytokines 
and chemokines. The membrane arrays revealed an increased expression of G-CSF, 
CXCL13 and CCL1 as well as IL-10 in the R-M, relative to LPS or IL-4 treated M 








Figure 2: Regulatory macrophage induction is independent of the STAT6 signaling 
pathway. BALB/c stat6-/- bone marrow derived macrophages were treated with 10 ng/ml 
LPS (L), a combination of LPS and 1µg of OVA opsonized with anti-OVA antibody (L+I), 
200 nM PGE2 (L+P), 200 μM adenosine (L+A), or 20 ng/ml IL-4 for 16 hours. The levels 
of IL-10 (A), IL-12/23p40 (B), IL-1β (C) and IL-6 (D) were measured in their supernatants 
by ELISA. Error bars indicate Mean ± SEM of three independent experiments. ***, p < 















Figure 3: Alternative Activated macrophage markers are dependent on the STAT6 
signaling pathway. BALB/c WT and stat6-/- bone marrow derived macrophages were 
treated with 10 ng/ml LPS (L), a combination of LPS and 1µg of OVA opsonized with 
anti-OVA antibody (L+I), 200 nM PGE2 (L+P), 200 μM adenosine (L+A), or 20 ng/ml IL-














Figure 4: Regulatory activation results in alterations of cytokine/chemokine profiles. 
Chemokine and cytokine secretion by BMDMs was measured by a proteome profiler 
membrane antibody array. Supernatants from non-stimulated macrophages were compared 
to macrophages treated with 10 ng/ml LPS, a combination of LPS and 5µg of OVA 
opsonized with anti-OVA antibody (L+I), 200 nM PGE2 (L+P), 200 μM adenosine (L+A) 
or 20 ng/ml IL-4 for 12 hours. The proteins that are of interest to this study are indicated 
in circles and the letters and numbers are provided to identify the position of the analyte in 
the membrane. Pooled supernatants collected from three independent experiments were 
added to a single membrane for each condition. Experiment was performed with the help 













Figure 5: Relative induction of cytokines/chemokines in activated macrophages. Mean 
fold differences in chemiluminescent intensity of the duplicate samples for relevant 
analytes are compared to intensities from non-stimulated. The alphanumeric values within 
parentheses indicate their position in the membrane array. Expression values for each 
conditions were determined from a single membrane assay that was incubated with 
supernatants from three independent experiments. Experiment was performed with the help 







in intensity in R-M (Figure 4, 5). All other cytokines and chemokines showed a similar 
intensity in both LPS treated M1-M and R-M. Most of the tested chemokines and 
cytokines showed little or no expression in AA-M, with the exception of CCL2, which 
was increased by two-fold over resting macrophages (Figure 4, 5). Together the data 
suggests that there are multiple ways to generate macrophages with immunoregulatory 
activity and that R-M exhibit a unique expression pattern of cytokines and chemokines 
that is clearly distinct from that of AA-M. 
3.4.2 RNA-seq Analysis of Murine Macrophages 
To further dissect the differences between the activation states of primary 
macrophages, we utilized high throughput RNA sequencing technology and generated 
RNA expression profiles for peritoneal macrophages stimulated under conditions similar 
to those used for bone marrow derived macrophages above. RNA expression levels of the 
cytokines il-10, il-12/23p40 and il-6 from peritoneal macrophages matched with the results 
we obtained for BMDM indicating that both macrophage populations are similarly capable 
of assuming a regulatory phenotype. Principal Component Analysis (PCA) revealed that 
AA-M cluster together with non-stimulated macrophages, whereas M1-M, RM-IC and 
RM-Ado align together along principal component 1 (the X axis), which accounts for a 
large majority of the variability observed between samples (>70%) (Figure 6A). Likewise, 
when Euclidean distance heat map analysis was used to visualize the relationships between 
the samples, IL-4 treated AA-M grouped closely with non-stimulated cells and the R-M 








Figure 6: Comparison of global RNA expression profiles of differentially activated 
macrophages. RNA-sequencing was performed on an Illumina platform comparing non-
stimulated (NS) murine macrophages and macrophages exposed to 10 ng/ml LPS, 10 ng/ml 
LPS and 5µg of OVA opsonized with anti-OVA antibody (L+I), 10 ng/ml LPS and 200 
μM adenosine (L+A) or 20 ng/ml IL-4. A principal components analysis (PCA) plot (A) 
and heat map of a hierarchical clustering analysis using the Euclidean distance metric (B) 
are shown. (A) In the PCA plot, each symbol represents an experimental sample with 
symbol color indicating macrophage treatment condition (gray = NS, orange = LPS, navy 
blue = L+I, medium blue = L+A, and green = IL-4) and symbol shape indicates batch. (B) 
Colors along the top of the heat map indicate the treatment condition (gray = NS, orange = 
LPS, navy blue = L+I, medium blue = L+A, and green = IL-4) and colors along the left 
side of the heat map indicate the batch/experimental date. This figure was generated 






immunoregulatory activity were transcriptionally distinct from IL-4-treated AA-M. 
Differential expression analysis was used to generate lists of genes that were greater 
than two-fold different between each macrophage population and non-stimulated 
macrophages (p<0.05). The two populations of R-M (RM-IC and RM-Ado) shared a 
total of 182 upregulated genes that were not significantly upregulated in the M1-M or 
AA-M populations. This group of gene represents core immunoregulatory genes can help 
describe how Regulatory macrophages function. Interestingly, there were only 15 genes 
upregulated by both R-M and AA-M, which suggests that R-M and AA-M have little 
functional overlap (Figure 7A). Similarly there were 261 unique genes downregulated in 
both R-M, but not in other macrophages, but only 14 genes were mutually downregulated 
in R-M and AA-M (Figure 7B). The core genes that were upregulated in R-M have the 
potential to be used as biomarkers for defining macrophages with immunoregulatory 
activity, and they may also provide further insight into the functions and phenotype of R-
M. It should be noted that the two populations of R-M showed some transcriptional 
diversity when compared. There were 385 genes were upregulated and 398 were 
downregulated in RM-IC. Similarly, 283 genes were upregulated and 314 genes were 
downregulated uniquely in RM-Ado (Figure 7A, 7B). These genes might explain how 
macrophages can tailor an immune response to combat a specific pathogen and provide 






Figure 7: Four way Venn diagrams of genes differentially expressed following 
activation. Overlap of differentially expressed genes upregulated (A) or downregulated 
(B) by greater than 2-fold relative to non-stimulated macrophages are displayed in Venn 
diagrams. Each large colored square represents the treatment condition (orange = LPS, 
navy blue = L+I, medium blue = L+A, and green = IL-4). This figure was generated 
through a collaboration with the El-Sayed lab by Laura Dillon. 





3.4.3 Differentially Expressed Genes 
Alternatively Activated macrophages and Regulatory macrophages are often 
grouped as the subset of M2-M45,55. However, our cytokine/chemokine profile, PCA, and 
heat map analyses shows that these macrophages are indeed different. To identify the genes 
that define each population, we analyzed the differentially expressed genes in each of the 
subsets. The first step to identify the genes that showed the highest level of upregulation in 
each condition. The expression values are expressed as log2 and were calculated by 
comparing the expression value in the stimulated condition to the non-stimulated condition. 
The top 100 genes for LPS (Table 2), LPS+immune complexes (Table 3), LPS+adenosine 
(Table 4) and IL-4 (Table 5) treatments are listed below. We see that cytokines like IL-6, 
IL-19, IL-12 and IL-23 are some of the most highly upregulated genes associated with LPS 
treatment. Additionally, our previously defined markers for murine AA-M, including 
ym1(chi3l3) & relmα (retnla) were confirmed by our RNA-seq analyses94. These tables are 
helpful in understanding the global changes that occur following the various stimulation, 
but make it difficult to compare gene expression levels in multiple parallel populations.  
Once we have the identified genes that were important for the various activation 
phenotypes, it was possible to identify genes that had a two-fold difference over the other 
populations. The top 25 genes that were induced in AA-M relative to all other stimulation 
conditions are listed in Table 6. These genes help to define alternative activation and the 
functions associated with these macrophages. To help remove LPS associated genes, we 





Table 2: Top 100 Upregulated Genes In LPS Treated Macrophages 
  Symbol Name (log2) 
1 u90926 cDNA sequence U90926 11.02 
2 csf3 colony stimulating factor 3 (granulocyte) 11.01 
3 nos2 nitric oxide synthase 2 inducible 10.02 
4 mmp3 matrix metallopeptidase 3 9.70 
5 il6 interleukin 6 9.62 
6 il19 interleukin 19 9.26 
7 il23a interleukin 23 alpha subunit p19 8.84 
8 il1f6 interleukin 1 family member 6 8.75 
9 csf2 colony stimulating factor 2 (granulocyte-macrophage) 8.74 
10 tpbpa trophoblast specific protein alpha 8.70 
11 lipg lipase endothelial 8.70 
12 saa1 serum amyloid A 1 8.49 
13 ccl4 chemokine (C-C motif) ligand 4 8.32 
14 ptgs2 prostaglandin-endoperoxide synthase 2 8.12 
15 steap4 STEAP family member 4 8.12 
16 il1b interleukin 1 beta 8.10 
17 ccl7 chemokine (C-C motif) ligand 7 8.08 
18 il12b interleukin 12b 7.87 
19 slamf1 signaling lymphocytic activation molecule family member 1 7.86 
20 lif leukemia inhibitory factor 7.69 
21 4732419C18Rik RIKEN cDNA 4732419C18 gene 7.68 
22 has1 hyaluronan synthase1 7.64 
23 saa2 serum amyloid A 2 7.50 
24 hunk hormonally upregulated Neu-associated kinase 7.47 
25 lcn2 lipocalin 2 7.46 
26 osmr oncostatin M receptor 7.39 
27 il1a interleukin 1 alpha 7.38 
28 ccl5 chemokine (C-C motif) ligand 5 7.32 
29 adamts4 a disintegrin-like and metallopeptidase with thromb. mo. 4 7.26 
30 gm14047 predicted gene 14042 7.12 
31 nid2 nidogen 2 7.04 
32 hdc histidine decarboxylase 7.04 
33 cxcl1 chemokine (C-X-C motif) ligand 1 6.99 
34 7530420F21Rik RIKEN cDNA 7530420F21 gene 6.96 





  Symbol Table 2(Cont.): Top 100 (log2) 
36 rnd1 Rho family GTPase 1 6.85 
37 mt2 metallothionein 2 6.78 
38 gja1 gap junction protein alpha 1 6.75 
39 armcx4 armadillo repeat containing X-linked 4 6.70 
40 trim30c tripartite motif-containing 30C 6.69 
41 gm16292 predicted gene 16286 6.67 
42 oasl1 2'-5' oligoadenylate synthetase-like 1 6.64 
43 ch25h cholesterol 25-hydroxylase 6.64 
44 areg Amphiregulin 6.63 
45 plat plasminogen activator tissue 6.56 
46 shisa3 shisa homolog 3  6.55 
47 ccl2 chemokine (C-C motif) ligand 2 6.50 
48 erich2 glutamate rich 2 6.49 
49 urah urate (5-hydroxyiso-) hydrolase 6.38 
50 upp1 uridine phosphorylase 1 6.31 
51 gm16685 predicted gene 16685 6.26 
52 rhou ras homolog gene family member U 6.21 
53 sptssb serine palmitoyltransferase small subunit B 6.20 
54 phlda1 pleckstrin homology-like domain family A member 1 6.18 
55 il22 interleukin 22 6.17 
56 inhba inhibin beta-A 6.16 
57 gm14023 predicted gene 14023 6.13 
58 ereg Epiregulin 6.13 
59 ifit1 interferon-induced protein with tetratricopeptide repeats 1 6.11 
60 nt5c1a 5'-nucleotidase cytosolic IA 6.10 
61 krt222 keratin 222 6.09 
62 gm4955 predicted gene 4955 6.07 
63 inhbb inhibin beta-B 6.06 
64 calcr calcitonin receptor 6.05 
65 rsad2 radical S-adenosyl methionine domain containing 2 6.04 
66 car4 carbonic anhydrase 4 6.04 
67 gm11435 predicted gene 11435 6.03 
68 isg15 ISG15 ubiquitin-like modifier 6.03 
69 ambp alpha 1 microglobulin/bikunin 5.98 





  Symbol Table 2(Cont.): Top 100 (log2) 
71 ppp1r3g protein phosphatase 1 regulatory (inhibitor) subunit 3G 5.93 
72 gm5483 predicted gene 5483 5.93 
73 timp1 tissue inhibitor of metalloproteinase 1 5.92 
74 ifitm7 interferon induced transmembrane protein 7 5.91 
75 hbegf heparin-binding EGF-like growth factor 5.89 
76 olfr56 olfactory receptor 56 5.88 
77 gm26667 predicted gene 26667 5.88 
78 il1rn interleukin 1 receptor antagonist 5.86 
79 gm26584 predicted gene 26584 5.83 
80 cxcl10 chemokine (C-X-C motif) ligand 10 5.82 
81 gm13822 predicted gene 13822 5.77 
82 cdh6 cadherin 6 5.77 
83 mx2 myxovirus (influenza virus) resistance 2 5.77 
84 gcnt2 glucosaminyl (N-acetyl) transferase 2 I-branching enzyme 5.76 
85 edn1 endothelin 1 5.75 
86 tnfsf15 tumor necrosis factor (ligand) superfamily member 15 5.71 
87 sele selectin  endothelial cell 5.67 
88 etnk2 ethanolamine kinase 2 5.65 
89 mbd3l2 methyl-CpG binding domain protein 3-like 2 5.58 
90 adora2b adenosine A2b receptor 5.47 
91 cxcl2 chemokine (C-X-C motif) ligand 2 5.47 
92 alpk2 alpha-kinase 2 5.47 
93 tarm1 T cell-interacting activating receptor on myeloid cells 1 5.44 
94 gm26687 predicted gene 26687 5.42 
95 il12a interleukin 12a 5.42 
96 fst Follistatin 5.41 
97 stfa3 stefin A3 5.41 
98 tmtc2 transmembrane and tetratricopeptide repeat containing 2 5.41 
99 il27 interleukin 27 5.38 
100 draxin dorsal inhibitory axon guidance protein 5.37 
The top 100 genes that were upregulated following treatment with LPS. Values were 
determined by calculating the induction over the non-stimulated condition and are expressed 






Table 3: Top 100 Upregulated Genes In LPS+Immune Complex Treated Macrophages 
  Symbol Name (log2) 
1 csf3 colony stimulating factor 3 (granulocyte) 11.61 
2 ccl7 chemokine (C-C motif) ligand 7 10.52 
3 ccl4 chemokine (C-C motif) ligand 4 9.31 
4 u90926 cDNA sequence U90926 9.29 
5 il6 interleukin 6 8.86 
6 lif leukemia inhibitory factor 8.80 
7 ptgs2 prostaglandin-endoperoxide synthase 2 8.74 
8 ccl2 chemokine (C-C motif) ligand 2 8.66 
9 slamf1 signaling lymphocytic activation molecule family member 1 8.50 
10 il1f6 interleukin 1 family member 6 8.47 
11 csf2 colony stimulating factor 2 (granulocyte-macrophage) 8.37 
12 saa1 serum amyloid A 1 8.13 
13 il10 interleukin 10 8.10 
14 mmp3 matrix metallopeptidase 3 7.94 
15 il1b interleukin 1 beta 7.78 
16 nos2 nitric oxide synthase 2 inducible 7.67 
17 gm26584 predicted gene 26584 7.57 
18 steap4 STEAP family member 4 7.53 
19 il19 interleukin 19 7.52 
20 cxcl1 chemokine (C-X-C motif) ligand 1 7.47 
21 il23a interleukin 23 alpha subunit p19 7.47 
22 inhba inhibin beta-A 7.42 
23 il1a interleukin 1 alpha 7.36 
24 tpbpa trophoblast specific protein alpha 7.34 
25 lipg lipase endothelial 7.29 
26 ccl3 chemokine (C-C motif) ligand 3 7.26 
27 ch25h cholesterol 25-hydroxylase 7.14 
28 has1 hyaluronan synthase1 7.04 
29 areg Amphiregulin 6.89 
30 osmr oncostatin M receptor 6.80 
31 il1rn interleukin 1 receptor antagonist 6.79 
32 samd11 sterile alpha motif domain containing 11 6.69 
33 urah urate (5-hydroxyiso-) hydrolase 6.68 
34 7530420F21Rik RIKEN cDNA 7530420F21 gene 6.63 





  Symbol Table 3(Cont.): Top 100 (log2) 
36 g530011O06Rik RIKEN cDNA G530011O06 gene 6.56 
37 isg15 ISG15 ubiquitin-like modifier 6.54 
38 kctd4 potassium channel tetramerisation domain containing 4 6.51 
39 mt2 metallothionein 2 6.47 
40 oasl1 2'-5' oligoadenylate synthetase-like 1 6.44 
41 pdpn Podoplanin 6.36 
42 trim30c tripartite motif-containing 30C 6.35 
43 stfa3 stefin A3 6.34 
44 gm21742 predicted gene 21742 6.31 
45 ildr1 immunoglobulin-like domain containing receptor 1 6.30 
46 gm14023 predicted gene 14023 6.28 
47 mbd3l2 methyl-CpG binding domain protein 3-like 2 6.27 
48 gm26667 predicted gene 26667 6.26 
49 htra4 htrA serine peptidase 4 6.25 
50 gm15726 predicted gene 15726 6.23 
51 ppp1r3g protein phosphatase 1 regulatory (inhibitor) subunit 3G 6.21 
52 saa2 serum amyloid A 2 6.20 
53 hbegf heparin-binding EGF-like growth factor 6.19 
54 niacr1 niacin receptor 1 6.18 
55 flrt3 fibronectin leucine rich transmembrane protein 3 6.16 
56 gm21857 predicted gene 21857 6.15 
57 gm14047 predicted gene 14042 6.12 
58 gm21748 predicted gene 21748 6.09 
59 gm5483 predicted gene 5483 6.06 
60 cxcl2 chemokine (C-X-C motif) ligand 2 6.04 
61 sphk1 sphingosine kinase 1 6.01 
62 erich2 glutamate rich 2 6.00 
63 gm15247 predicted gene 15247 6.00 
64 xcr1 chemokine (C motif) receptor 1 6.00 
65 cd209a CD209a antigen 6.00 
66 rsad2 radical S-adenosyl methionine domain containing 2 5.93 
67 gm16292 predicted gene 16286 5.93 
68 ereg Epiregulin 5.92 
69 gja1 gap junction protein alpha 1 5.86 





  Symbol Table 3(Cont.): Top 100 (log2) 
71 phlda1 pleckstrin homology-like domain family A member 1 5.85 
72 gm21860 predicted gene 21860 5.83 
73 gng4 guanine nucleotide binding protein (G protein) gamma 4 5.82 
74 il33 interleukin 33 5.81 
75 upp1 uridine phosphorylase 1 5.79 
76 tnf tumor necrosis factor 5.78 
77 edn1 endothelin 1 5.73 
78 aw011738 expressed sequence AW011738 5.72 
79 f3 coagulation factor III 5.70 
80 gm26687 predicted gene 26687 5.69 
81 gm16685 predicted gene 16685 5.69 
82 gcnt2 glucosaminyl (N-acetyl) transferase 2 I-branching enzyme 5.67 
83 car4 carbonic anhydrase 4 5.65 
84 gm4955 predicted gene 4955 5.63 
85 gm5416 predicted gene 5416 5.61 
86 ccl5 chemokine (C-C motif) ligand 5 5.60 
87 gdf15 growth differentiation factor 15 5.58 
88 1600029D21Rik RIKEN cDNA 1600029D21 gene 5.57 
89 gfpt2 glutamine fructose-6-phosphate transaminase 2 5.54 
90 ifit1 interferon-induced protein with tetratricopeptide repeats 1 5.53 
91 gm13822 predicted gene 13822 5.50 
92 nt5c1a 5'-nucleotidase cytosolic IA 5.42 
93 timp1 tissue inhibitor of metalloproteinase 1 5.40 
94 adamts4 a disintegrin-like and metallopeptidase with thromb. mo 4 5.38 
95 ckap2l cytoskeleton associated protein 2-like 5.38 
96 ndrg1 N-myc downstream regulated gene 1 5.38 
97 gm8818 predicted pseudogene 8818 5.36 
98 itga2 integrin alpha 2 5.35 
99 alpk2 alpha-kinase 2 5.31 
100 drd1a dopamine receptor D1A 5.27 
The top 100 genes that were upregulated following treatment with LPS+immune complexes. 
Values were determined by calculating the induction over the non-stimulated condition and 






Table 4: Top 100 Upregulated Genes In LPS+Adenosine Treated Macrophages 
  Symbol Name (log2) 
1 u90926 cDNA sequence U90926 10.83 
2 csf3 colony stimulating factor 3 (granulocyte) 10.15 
3 csf2 colony stimulating factor 2 (granulocyte-macrophage) 9.61 
4 sele selectin endothelial cell 9.57 
5 il33 interleukin 33 9.13 
6 nos2 nitric oxide synthase 2 inducible 9.11 
7 il19 interleukin 19 9.00 
8 has1 hyaluronan synthase1 8.87 
9 lif leukemia inhibitory factor 8.79 
10 steap4 STEAP family member 4 8.73 
11 il6 interleukin 6 8.73 
12 lipg lipase endothelial 8.53 
13 gm14047 predicted gene 14042 8.31 
14 tpbpa trophoblast specific protein alpha 8.28 
15 saa1 serum amyloid A 1 8.18 
16 ccl7 chemokine (C-C motif) ligand 7 8.18 
17 ptgs2 prostaglandin-endoperoxide synthase 2 8.13 
18 il1f6 interleukin 1 family member 6 7.98 
19 mmp3 matrix metallopeptidase 3 7.89 
20 urah urate (5-hydroxyiso-) hydrolase 7.86 
21 adamts4 a disintegrin-like and metallopeptidase with thromb. mo.4 7.82 
22 4732419C18Rik RIKEN cDNA 4732419C18 gene 7.67 
23 il23a interleukin 23 alpha subunit p19 7.66 
24 areg Amphiregulin 7.63 
25 il1b interleukin 1 beta 7.57 
26 7530420F21Rik RIKEN cDNA 7530420F21 gene 7.53 
27 osmr oncostatin M receptor 7.51 
28 ereg Epiregulin 7.42 
29 plat plasminogen activator tissue 7.36 
30 hc hemolytic complement 7.35 
31 il1a interleukin 1 alpha 7.32 
32 dusp14 dual specificity phosphatase 14 7.31 
33 gja1 gap junction protein alpha 1 7.31 
34 gfpt2 glutamine fructose-6-phosphate transaminase 2 7.31 





  Symbol Table 4(Cont.): Top 100 (log2) 
36 tpbg trophoblast glycoprotein 7.27 
37 nid2 nidogen 2 7.26 
38 ifi202b interferon activated gene 202B 7.20 
39 nptx2 neuronal pentraxin 2 7.06 
40 cxcl1 chemokine (C-X-C motif) ligand 1 7.00 
41 slamf1 signaling lymphocytic activation molecule family member 1 6.99 
42 rnd1 Rho family GTPase 1 6.90 
43 klk9 kallikrein related-peptidase 9 6.80 
44 hdc histidine decarboxylase 6.79 
45 hunk hormonally upregulated Neu-associated kinase 6.77 
46 slco2b1 solute carrier organic anion transporter family member 2b1 6.75 
47 erich2 glutamate rich 2 6.72 
48 gzmb granzyme B 6.72 
49 inhba inhibin beta-A 6.61 
50 saa2 serum amyloid A 2 6.58 
51 hist1h3e histone cluster 1 H3e 6.51 
52 gm4847 predicted gene 4847 6.50 
53 gm16292 predicted gene 16286 6.49 
54 1600029D21Rik RIKEN cDNA 1600029D21 gene 6.49 
55 flrt3 fibronectin leucine rich transmembrane protein 3 6.48 
56 trim30c tripartite motif-containing 30C 6.45 
57 ccl2 chemokine (C-C motif) ligand 2 6.41 
58 gm5483 predicted gene 5483 6.38 
59 phlda1 pleckstrin homology-like domain family A member 1 6.37 
60 rhou ras homolog gene family member U 6.35 
61 sptssb serine palmitoyltransferase small subunit B 6.34 
62 lcn2 lipocalin 2 6.28 
63 mt2 metallothionein 2 6.26 
64 il10 interleukin 10 6.26 
65 gm5416 predicted gene 5416 6.25 
66 upp1 uridine phosphorylase 1 6.23 
67 etnk2 ethanolamine kinase 2 6.20 
68 tnfaip6 tumor necrosis factor alpha induced protein 6 6.18 
69 ifitm7 interferon induced transmembrane protein 7 6.17 





 Symbol Table 4(Cont.): Top 100 (log2) 
71 gm26584 predicted gene 26584 6.12 
72 tmtc2 transmembrane and tetratricopeptide repeat containing 2 6.10 
73 ccl5 chemokine (C-C motif) ligand 5 6.10 
74 penk Preproenkephalin 6.04 
75 gm14023 predicted gene 14023 6.02 
76 arc activity regulated cytoskeletal-associated protein 5.98 
77 tnfrsf9 tumor necrosis factor receptor superfamily  member 9 5.98 
78 drd1a dopamine receptor D1A 5.95 
79 ckap2l cytoskeleton associated protein 2-like 5.91 
80 niacr1 niacin receptor 1 5.91 
81 il1rn interleukin 1 receptor antagonist 5.89 
82 gm8818 predicted pseudogene 8818 5.88 
83 inhbb inhibin beta-B 5.88 
84 gcnt2 glucosaminyl (N-acetyl) transferase 2 I-branching enzyme 5.86 
85 hist1h4c histone cluster 1 H4c 5.85 
86 gm26667 predicted gene 26667 5.85 
87 hbegf heparin-binding EGF-like growth factor 5.83 
88 adora2b adenosine A2b receptor 5.82 
89 dusp2 dual specificity phosphatase 2 5.81 
90 pxdc1 PX domain containing 1 5.76 
91 gm26687 predicted gene 26687 5.75 
92 gm13889 predicted gene 13889 5.74 
93 gdnf glial cell line derived neurotrophic factor 5.70 
94 tslp thymic stromal lymphopoietin 5.70 
95 il22 interleukin 22 5.68 
96 stfa3 stefin A3 5.65 
97 timp1 tissue inhibitor of metalloproteinase 1 5.65 
98 trem1 triggering receptor expressed on myeloid cells 1 5.63 
99 shisa3 shisa homolog 3  5.61 
100 ccl3 chemokine (C-C motif) ligand 3 5.61 
The top 100 genes that were upregulated following treatment with LPS+adenosine. Values were 
determined by calculating the induction over the non-stimulated condition and are expressed as 






Table 5: Top 100 Upregulated Genes In IL-4 Treated Macrophages 
 Symbol Name (log2) 
1 chi3l3 checkpoint with forkhead and ring finger domains 8.60 
2 itgb3 integrin beta 3 6.69 
3 cd209e CD209e antigen 6.49 
4 flt1 FMS-like tyrosine kinase 1 6.26 
5 serpina3g serine (or cysteine) peptidase inhibitor clade A member 3G 6.11 
6 gm8221 predicted gene 8221 6.11 
7 ear11 eosinophil-associated ribonuclease A family member 11 5.89 
8 slc7a2 solute carrier family 7 member 2 5.69 
9 pdcd1lg2 programmed cell death 1 ligand 2 5.68 
10 chi3l4 checkpoint with forkhead and ring finger domains 5.61 
11 cdh1 cadherin 1 5.44 
12 tmem26 transmembrane protein 26 5.25 
13 il4i1 interleukin 4 induced 1 5.08 
14 il31ra interleukin 31 receptor A 5.04 
15 cish cytokine inducible SH2-containing protein 4.97 
16 peg10 paternally expressed 10 4.96 
17 tslp thymic stromal lymphopoietin 4.94 
18 apol7c apolipoprotein L 7c 4.93 
19 mrc1 mannose receptor C type 1 4.91 
20 ccl7 chemokine (C-C motif) ligand 7 4.78 
21 ddx4 DEAD (Asp-Glu-Ala-Asp) box polypeptide 4 4.71 
22 socs1 suppressor of cytokine signaling 1 4.69 
23 retnla resistin like alpha 4.69 
24 gatm glycine amidinotransferase  4.66 
25 en2 engrailed 2 4.55 
26 hbegf heparin-binding EGF-like growth factor 4.54 
27 mgl2 macrophage galactose N-acetyl-galactosamine specific lectin 2 4.54 
28 ccl12 chemokine (C-C motif) ligand 12 4.46 
29 insrr insulin receptor-related receptor 4.44 
30 irf4 interferon regulatory factor 4 4.32 
31 lipn lipase  family member N 4.27 
32 batf3 basic leucine zipper transcription factor ATF-like 3 4.25 
33 tuba8 tubulin  alpha 8 4.07 
34 gm26584 predicted gene 26584 4.03 





  Symbol Table 5 (Cont.): Top 100 (log2) 
36 alox15 arachidonate 15-lipoxygenase 3.88 
37 apol7b apolipoprotein L 7b 3.83 
38 car4 carbonic anhydrase 4 3.81 
39 rab3il1 RAB3A interacting protein (rabin3)-like 1 3.77 
40 il20rb interleukin 20 receptor beta 3.65 
41 dixdc1 DIX domain containing 1 3.64 
42 nrg1 neuregulin 1 3.62 
43 tfrc transferrin receptor 3.58 
44 slc30a4 solute carrier family 30 (zinc transporter) member 4 3.58 
45 plekhf1 pleckstrin homology domain containing family F member 1 3.52 
46 klf4 kruppel-like factor 4 (gut) 3.49 
47 gm6116 predicted gene 6116 3.47 
48 prps1 phosphoribosyl pyrophosphate synthetase 1 3.43 
49 ch25h cholesterol 25-hydroxylase 3.43 
50 pcyox1l prenylcysteine oxidase 1 like 3.39 
51 scimp SLP adaptor and CSK interacting membrane protein 3.36 
52 b3gnt7 betaGal beta-1 3-N-acetylglucosaminyltransferase 7 3.32 
53 cd83 CD83 antigen 3.32 
54 btbd11 BTB (POZ) domain containing 11 3.29 
55 ccl24 chemokine (C-C motif) ligand 24 3.24 
56 hid1 HID1 domain containing 3.22 
57 htr2a 5-hydroxytryptamine (serotonin) receptor 2A 3.21 
58 atp8b1 ATPase class I type 8B member 1 3.15 
59 6430571L13Rik RIKEN cDNA 6430571L13 gene 3.13 
60 slc14a1 solute carrier family 14 (urea transporter) member 1 3.12 
61 rhoj ras homolog gene family member J 3.02 
62 sdc4 syndecan 4 3.00 
63 dnah12 dynein axonemal heavy chain 12 2.98 
64 apol7e apolipoprotein L 7e 2.97 
65 pxdc1 PX domain containing 1 2.97 
66 rasgrp1 RAS guanyl releasing protein 1 2.96 
67 lad1 Ladinin 2.94 
68 na NA 2.93 
69 fgf2 fibroblast growth factor 2 2.91 





  Symbol Table 5 (Cont.): Top 100 (log2) 
71 ms4a8a membrane-spanning 4-domains subfamily A member 8A 2.85 
72 tarm1 T cell-interacting activating receptor on myeloid cells 1 2.85 
73 rgl1 ral guanine nucleotide dissociation stimulator -like 1 2.83 
74 itga1 integrin alpha 1 2.82 
75 ramp3 receptor (calcitonin) activity modifying protein 3 2.82 
76 cd209a CD209a antigen 2.80 
77 amica1 adhesion molecule interacts with CXADR antigen 1 2.80 
78 p2ry1 purinergic receptor P2Y  G-protein coupled 1 2.78 
79 fndc7 fibronectin type III domain containing 7 2.76 
80 wnt2 wingless-related MMTV integration site 2 2.75 
81 bcar3 breast cancer anti-estrogen resistance 3 2.73 
82 2810055G20Rik RIKEN cDNA 2810055G20 gene 2.71 
83 ido2 indoleamine 2 3-dioxygenase 2 2.70 
84 ptpro protein tyrosine phosphatase receptor type  O 2.69 
85 arg1 arginase liver 2.68 
86 cyp1b1 cytochrome P450 family 1 subfamily b polypeptide 1 2.68 
87 flrt3 fibronectin leucine rich transmembrane protein 3 2.67 
88 olfm1 olfactomedin 1 2.65 
89 adcy3 adenylate cyclase 3 2.65 
90 upp1 uridine phosphorylase 1 2.63 
91 ccl2 chemokine (C-C motif) ligand 2 2.63 
92 cd40 CD40 antigen 2.60 
93 fyn Fyn proto-oncogene 2.56 
94 egr2 early growth response 2 2.56 
95 pald1 phosphatase domain containing paladin 1 2.55 
96 sfrp1 secreted frizzled-related protein 1 2.52 
97 serpina3f serine (or cysteine) peptidase inhibitor clade A member 3F 2.52 
98 fchsd2 FCH and double SH3 domains 2 2.51 
99 ttll11 tubulin tyrosine ligase-like family member 11 2.51 
100 flrt2 fibronectin leucine rich transmembrane protein 2 2.49 
The top 100 genes that were upregulated following treatment with IL-4. Values were determined 








Table 6. Top 25 Genes Uniquely Induced Following IL-4 Stimulation 
 Symbol Name (log2) 
1 chi3l3 checkpoint with forkhead and ring finger domains 8.60 
2 itgb3 integrin beta 3 6.69 
3 cd209e CD209e antigen 6.49 
4 flt1 FMS-like tyrosine kinase 1 6.26 
5 serpina3g serine (or cysteine) peptidase inhibitor clade A member 3G 6.11 
6 gm8221 predicted gene 8221 6.11 
7 ear11 eosinophil-associated ribonuclease A family member 11 5.89 
8 pdcd1lg2 programmed cell death 1 ligand 2 5.68 
9 chi3l4 checkpoint with forkhead and ring finger domains 5.61 
10 cdh1 cadherin 1 5.44 
11 tmem26 transmembrane protein 26 5.25 
12 il4i1 interleukin 4 induced 1 5.08 
13 il31ra interleukin 31 receptor A 5.04 
14 apol7c apolipoprotein L 7c 4.93 
15 mrc1 mannose receptor C type 1 4.91 
16 ddx4 DEAD (Asp-Glu-Ala-Asp) box polypeptide 4 4.71 
17 retnla resistin like alpha 4.69 
18 gatm glycine amidinotransferase 4.66 
19 en2 engrailed 2 4.55 
20 mgl2 macrophage galactose N-acetyl-galactosamine specific lectin 2 4.54 
21 insrr insulin receptor-related receptor 4.44 
22 irf4 interferon regulatory factor 4 4.32 
23 lipn lipase family member N 4.27 
24 batf3 basic leucine zipper transcription factor ATF-like 3 4.25 
25 tuba8 tubulin alpha 8 4.07 
The top 25 genes that were induced following IL-4 treatment. All of these genes have at least 
a two-fold upregulation over LPS, LPS+immune complex and LPS+adenosine treated 
expression levels. Values were determined by calculating the induction over the non-






considered these to be immunoregulatory genes. As expected, IL-10 was one of the first 
few on the list with the immune regulatory functions (Table 7). For the first time we gaining 
a comprehensive understanding of the core genes shared between differentially activated 
Regulatory macrophage populations. Among this list, was 26 genes had no known function 
(Table 8). These genes helps to highlight the fact that macrophage activation responses 
have not been fully describe and that there may be important factors yet to be discovered. 
3.4.4 Activated ‘Diseases and Function’ Identified by IPA Analysis 
The Ingenuity Pathway Analysis (IPA) platform was used to identify differences in 
‘Diseases and Functions’ associations between the two R-M and the LPS treated M1-M. 
The attributes most closely associated with RM-IC were development of blood vessels, 
the proliferation of liver cells and the development of tumors (Figure 8A). As expected, 
RM-IC downregulated myeloid cells activation and the induction of TH1-associated 
functions (Figure 8A). The RM-Ado shared vascularization functions with RM-IC and 
reduced anti-microbial responses (Figure 8B). This IPA analysis helped confirm that one 
of the primary functions of R-M is to limit immune responses and help to repair tissue 
that has been damaged. The previously reported functions associated with LPS 
stimulation44,106-108 were confirmed by our RNA-seq and IPA analysis and includes the 
activation of strong inflammatory immune responses (Figure 9A). AA-M appeared to be 
associated with maintaining connective tissue and general tissue development (Figure 9B), 
thus agreeing with previously described phenotypes for these cells53,55. The IPA analysis 







Table 7. Genes Induced Following Regulatory Activation 





1 lif leukemia inhibitory factor 8.80 8.79 
2 il10 interleukin 10 8.10 6.26 
3 ildr1 immunoglobulin-like domain containing receptor 1 6.30 4.25 
4 flrt3 fibronectin leucine rich transmembrane protein 3 6.16 6.48 
5 xcr1 chemokine (C motif) receptor 1 6.00 4.79 
6 il33 interleukin 33 5.81 9.13 
7 ckap2l cytoskeleton associated protein 2-like 5.38 5.91 
8 ndrg1 n-myc downstream regulated gene 1 5.38 5.05 
9 itga2 integrin alpha 2 5.35 4.95 
10 gem GTP binding protein 5.24 4.28 
11 mid1 midline 1 5.05 3.65 
12 odc1 ornithine decarboxylase structural 1 5.05 5.58 
13 hephl1 hephaestin-like 1 5.03 5.12 
14 gdnf glial cell line derived neurotrophic factor 4.94 5.70 
15 klk9 kallikrein related-peptidase 9 4.60 6.80 
16 dusp14 dual specificity phosphatase 14 4.59 7.31 
17 gprc5a g protein-coupled receptor family C group 5 member A 4.44 3.76 
18 tmem88 transmembrane protein 88 4.37 5.04 
19 hrc histidine rich calcium binding protein 4.20 2.68 
20 nptx2 neuronal pentraxin 2 3.84 7.06 
21 dusp10 dual specificity phosphatase 10 3.72 3.52 
22 hc hemolytic complement 3.59 7.35 
23 cdk6 cyclin-dependent kinase 6 3.27 2.89 
24 tmem236 transmembrane protein 236 3.26 3.35 
25 fam71f2 family with sequence similarity 71 member F2 3.19 4.30 
The top 25 genes that were induced following LPS+immune complex treatment and 
LPS+adenosine treatment. All of these genes have at least a two-fold upregulation over 
both the LPS treated and IL-4 treated expression levels. Values were determined by 









Table 8. Shared Predicted Genes Induced Following Regulatory Activation 





1 gm21742 predicted gene 21742 6.31 4.61 
2 gm15726 predicted gene 15726 6.23 4.63 
3 gm21857 predicted gene 21857 6.15 4.74 
4 gm21748 predicted gene 21748 6.09 3.91 
5 gm15247 predicted gene 15247 6.00 4.47 
6 gm3513 predicted gene 3513 5.85 3.78 
7 gm21860 predicted gene 21860 5.83 3.91 
8 gm8818 predicted pseudogene 8818 5.36 5.88 
9 gm22748 predicted gene 22748 4.76 4.46 
10 gm14636 predicted gene 14636 4.49 3.22 
11 gm8174 predicted gene 8174 4.33 5.09 
12 gm26603 predicted gene 26603 4.22 3.21 
13 gm7120 predicted gene 7120 4.10 1.71 
14 gm26772 predicted gene 26772 3.63 2.30 
15 gm6611 predicted gene 6611 3.42 3.60 
16 gm13889 predicted gene 13889 3.05 5.74 
17 gm11870 predicted gene 11870 2.61 2.72 
18 gm17709 predicted gene 17709 2.59 2.24 
19 gm9797 predicted pseudogene 9797 2.48 1.40 
20 gm16596 predicted gene 16596 2.21 1.87 
21 gm16310 predicted gene 16310 2.19 3.38 
22 gm24357 predicted gene 24357 1.56 1.32 
23 gm21769 predicted gene 21769 1.49 1.56 
24 gm9982 predicted gene 9982 1.42 1.29 
25 gm26767 predicted gene 26767 1.40 1.39 
26 gm16184 predicted gene 16184 1.24 1.14 
The 26 predicted genes/pseudogenes that were induced following LPS+immune 
complex treatment and LPS+adenosine treatment. All of these genes have at least a two-
fold up-regulation over both the LPS treated and IL-4 treated expression levels. Values 
were determined by calculating the induction over the non-stimulated condition and are 







Figure 8: Top activated and repressed ‘Diseases and Function’ associated with regulatory 
activation in macrophages. The changes associated with ‘Diseases and Functions’ in R-M were 
predicted by Ingenuity pathway analysis program. Genes that showed a changed in L+I (A) or L+A 
(B) of at least two-fold when compared to M1-M were selected to identify pathways associated 
with regulatory functions. Fold changes were uploaded to IPA and the ‘Diseases and Functions’ 
predicted to be altered based on a significant z-score were selected for these graphs. A z-score 
above 1.65 (activated) or below -1.65 (inhibited) is considered statistically significant. Figure was 








Figure 9: Top 15 activated ‘Diseases and Function’ associated with M1 and Alternatively 
Activated macrophages. Top 15 activated pathways associated with ‘Diseases and Functions’ 
predicted by Ingenuity Pathway Analysis Program are shown for M1-M (A) and AA-M (B). 
Data is expressed as a Z-score which was generated by comparing the stimulated conditions to the 
non-stimulated resting macrophages. A Z-score of 1.65 or greater indicates statistical significance. 





3.4.5 Metabolism in Regulatory Activation is Similar to that of LPS Treated Cells 
Several studies have identified metabolic alterations among the various 
macrophage activation states109-111. Applying IPA to the RNA-seq data identified several 
metabolic changes that occurred in both LPS stimulated M1-M and R-M, but not in IL-
4 treated AA-M (Table 9). To confirm the metabolic differences predicted by IPA, the 
consumption of glucose and the production of L-lactate was experimentally determined. 
Glucose consumption by the three R-M populations was comparable to M1-M, and 
much higher than IL-4-treated AA-M which was comparable to non-stimulated cells 
(Figure 10A). Similarly, the secretion of L-lactate, a metabolic product of the fermentation 
pathway, was higher in M1-M and R-M relative to IL-4 treated AA-M (Figure 10B). 
These results suggest that R-M share metabolic similarities with LPS treated M1-M and 
are distinct from AA-M. Additionally, it indicated that changes in metabolism might be 















Table 9: Metabolic Pathways Identified by IPA Analysis (Z-score) 
Canonical Pathways related to energy metabolism LPS L+I  L+A IL-4  
Pentose phosphate pathway (Oxidative branch) 2.54 2.37 2.42 0.73 
Pentose phosphate pathway 2.43 2.20 2.26 0.44 
Fatty acid β-oxidation I 1.82 2.46 3.12 0.00 
Glycogen degradation II 1.89 1.70 2.53 0.00 
Glycogen degradation III 2.19 1.33 2.79 0.00 
Gluconeogenesis I 1.66 3.73 1.06 0.21 
Oleate biosynthesis II (animals) 0.85 1.77 1.82 0.00 
Glycolysis I 1.12 3.51 0.97 0.00 
The top energy metabolism related canonical pathways that shows significant 
upregulation in at least one of the four conditions analyzed by RNA-seq. Numbers 
are expressed as the Z-score which was generated from a Fisher's Exact test when 
comparing stimulated to non-stimulated macrophages. Numbers that had a Z-score 












Figure 10: Glucose and lactate production in Regulatory macrophages. BMDMs were 
left unstimulated or stimulated with 10 ng/ml LPS, a combination of LPS and 1µg of OVA 
opsonized with anti-OVA antibody (L+I), 200 nM PGE2 (L+P), 200 μM adenosine (L+A), 
or 20 ng/ml IL-4 for 24 hours. (A) Glucose consumption was determined 24 hours post 
stimulation by an enzymatic assay as described in materials and methods. (B) L-lactate 
concentrations in the supernatants were obtained 8 hours post stimulation by utilizing the 
NADH-coupled enzyme reaction that reduces tetrazolim salt to formazan which is 
measured at an absorbance of 490 nm.  Error bars indicate Mean ± SEM of four 
independent experiments. Statistics were determined by comparing the various activation 
conditions to the non-stimulated condition. ***, p < 0.001. **, p < 0.01. *, p < 0.05. Figure 








3.4.6 Identification of Candidate Biomarkers 
To validate the RNA-seq analyses, qRT-PCR was performed to examine several 
regulatory and AA-M associated genes. Activation states were confirmed through the 
examination of well-established markers (Figure 11). Among the tested genes, the mRNA 
levels of il-33, flrt3, and ccr1 were induced in all regulatory conditions, but not by LPS or 
IL-4 stimulation (Figure 12). The mutual upregulation of these cells in Regulatory 
macrophages suggests that these genes play an important roles in the immunoregulatory 
phenotype. These studies were repeated in the stat6-/- mice to determine if their inductions 
was independent of STAT6 signaling. The induction profiles were indeed similar to those 
observed in the wild type mice (Figure 13). Thus, these genes represent potential 
biomarkers for R-M.  
Additionally, genes were found to be associated with a single stimulatory 
conditions. Some genes were induced in individual regulatory populations but not shared 
by all three R-M. For example, mRNAs encoding gem, ildr1, and emp1 were induced in 
RM-IC, but not in RM-PGE2/RM-Ado (Figure 14). The unique induction of these 
genes suggests that not all Regulatory macrophages are the same, but rather are related by 
a group of core genes. Similarly, the mRNA expression of il-4i1, earl1 and cd209e was 
specifically induced in AA-M (Figure 15). The fact that not of these genes were associated 
with regulatory activation suggests that the function of AA-M is distinct from R-M. Like 
before, these genes were tested to determine if they were dependent on STAT6 signaling. 








Figure 11: Induction profiles of control genes in activated macrophages. Real time-
PCR analyses were performed at indicated time points on cDNA obtained from WT 
BALB/c BMDMs, which were left unstimulated or stimulated with 10 ng/ml LPS, a 
combination of LPS and 5µg of OVA opsonized with anti-OVA antibody (L+I), 200 nM 
PGE2 (L+P), 200 μM adenosine (L+A) or 20 ng/ml IL-4. Graphs for il-10 (A), il-12/23p40 
(B), ym1 (C), and relm (D) are shown. Each data point represents mean value ± SEM 






Figure 12: Induction profiles of regulatory genes in activated macrophages. Real time-
PCR analyses were performed at indicated time points on cDNA obtained from BALB/c 
WT BMDMs, which were left unstimulated or stimulated with 10 ng/ml LPS, a 
combination of LPS and 5µg of OVA opsonized with anti-OVA antibody (L+I), 200 nM 
PGE2 (L+P), 200 μM adenosine (L+A) or 20 ng/ml IL-4. Graphs for il-33 (A), flrt3 (B), 
and ccr1 (C) are shown. Each data point represents mean value ± SEM from duplicate 






Figure 13: Induction profiles of regulatory genes in activated macrophages is 
independent of STAT6 signaling. Real time-PCR analyses were performed at indicated 
time points on cDNA obtained from BALB/c stat6-/- BMDMs, which were left 
unstimulated or stimulated with 10 ng/ml LPS, a combination of LPS and 5µg of OVA 
opsonized with anti-OVA antibody (L+I), 200 nM PGE2 (L+P), 200 μM adenosine (L+A) 
or 20 ng/ml IL-4. Graphs for il-33 (A), flrt3 (B), and ccr1 (C) are shown. Each data point 






Figure 14: Induction profiles of immune complex induced genes in activated 
macrophages. Real time-PCR analyses were performed at indicated time points on cDNA 
obtained from BALB/c WT BMDMs, which were left unstimulated or stimulated with 10 
ng/ml LPS, a combination of LPS and 5µg of OVA opsonized with anti-OVA antibody 
(L+I), 200 nM PGE2 (L+P), 200 μM adenosine (L+A) or 20 ng/ml IL-4. Graphs for gem 
(A), ildr1 (B), and emp1 (C) are shown. Each data point represents mean value ± SEM 






Figure 15: Induction profiles of IL-4 induced genes in activated macrophages. Real 
time-PCR analyses were performed at indicated time points on cDNA obtained from 
BALB/c WT BMDMs, which were left unstimulated or stimulated with 10 ng/ml LPS, a 
combination of LPS and 5µg of OVA opsonized with anti-OVA antibody (L+I), 200 nM 
PGE2 (L+P), 200 μM adenosine (L+A) or 20 ng/ml IL-4. Graphs for il-4i1 (A), ear11 (B), 
and cd209e (C) are shown. Each data point represents mean value ± SEM from duplicate 





independent, but the genes associated with IL-4 stimulation were STAT6 dependent 
(Figure 16). This helps to highlight a fundamental difference in how these genes are 
induced and how they help to define the different activation states.  
There were additional qRT-PCR validations performed on genes found in Table 7. 
Genes that showed increased expression for at least one regulatory condition were ndrg1, 
klk9, dusp14, hc, tnfsf14 and cd244 (Figure 17). Analysis of lif, xcr1, mid1, and mospd4 
revealed that these genes were not associated with regulatory conditions or were below the 
level of detection (Figure 18). The failed validation of these genes could indicate 
differences in how bone marrow derived and peritoneal macrophages regulate gene 
expression. 
3.4.7 Detecting Candidate Biomarkers on the Protein Level  
Chemokine receptors form an important component of immune responses and the 
polarized macrophages subsets exhibit differences in their surface chemokine receptor 
expression46. To correlate transcription with surface protein levels, we performed flow 
cytometric analysis of CCR1 surface expression on the different macrophage populations. 
There was a 3-4 fold increase in mean fluorescent intensity (MFI) observed in all of the R-
M, with only a 2 fold induction in the LPS treated cells and no induction in IL-4 treated 
cells (Figure 19). Thus, CCR1 represents a potential biomarker for R-M and suggests that 












Figure 16: Induction of immune complex induced genes is independent of STAT6 
signaling in activated macrophages. Real time-PCR analyses of immune complex 
induced genes (A) and IL-4 induced (B) genes were performed at 2 hours and 6 hours, 
respectively. BALB/c WT and stat6-/- BMDMs were stimulated LPS and 5µg of OVA 
opsonized with anti-OVA antibody or 20 ng/ml IL-4. Relative expression was determined 
by a comparison with non-stimulated cells. Each error bar represents mean value ± SEM 












Figure 17: Validation of regulatory gene candidates in activated macrophages. Real 
time-PCR analyses were performed at indicated time points on cDNA obtained from WT 
BALB/c BMDMs, which were left unstimulated or stimulated with 10 ng/ml LPS, a 
combination of LPS and 5µg of OVA opsonized with anti-OVA antibody (L+I), 200 nM 
PGE2 (L+P), 200 μM adenosine (L+A) or 20 ng/ml IL-4. Graphs for ndrg1 (A), klk9 (B), 
dusp14 (C), hc (D), tnfsf14 (E), and cd244 (F) are shown. Each data point represents mean 








Figure 18: Failed validation of regulatory gene candidates in activated macrophages. 
Real time-PCR analyses were performed at indicated time points on cDNA obtained from 
WT BALB/c BMDMs, which were left unstimulated or stimulated with 10 ng/ml LPS, a 
combination of LPS and 5µg of OVA opsonized with anti-OVA antibody (L+I), 200 nM 
PGE2 (L+P), 200 μM adenosine (L+A) or 20 ng/ml IL-4. Graphs for lif (A), xcr1 (B), mid1 
(C), and mospd4 (D) are shown. Each data point represents mean value ± SEM from 









Figure 19: CCR1 expression is associated with regulatory activation of macrophages. 
BALB/c WT BMDMs, which were left unstimulated or stimulated with 10 ng/ml LPS, a 
combination of LPS and 5µg of OVA opsonized with anti-OVA antibody (L+I), 200 nM 
PGE2 (L+P), 200 μM adenosine (L+A) or 20 ng/ml IL-4. Surface expression of CCR1 was 
assessed by flow cytometry using a PE-conjugated antibody after 24 hours of stimulation. 
A representative histogram (A) and the fold induction in CCR1 mean fluorescence intensity 
(MFI) over non-stimulated cells is represented from five separate experiments (B) are 
shown here. The mean values are represented with SEM and statistics were determined 
through a comparison to the LPS condition. *, ** represents p<0.05, 0.01, respectively. 








3.4.8 Regulatory Activation Offers Protection from Lethal Endotoxin Challenge 
The production of IL-10 by the macrophage has been identified as an important 
component in sparing mice from lethal endotoxemia112,113. We hypothesized that the R-M 
should offer protection against lethal endotoxin challenge. To test this, we adoptively 
transferred the various R-M and AA-M into the peritoneum of mice, followed by 
intraperitoneal injection of a lethal dose of LPS (endotoxin). All three R-M populations 
provided some level of protection to mice receiving endotoxin. Mice that received RM-
IC showed a 90% survival, whereas mice that received RM-PGE2 or RM-Ado showed 
survival rates of 70% and 50%, respectively. In contrast, 80% of mice receiving resting 
unstimulated M succumbed to lethal endotoxemia. Parallel groups of mice receiving a 
transfer of IL-4-treated AA-M were not protected from lethal endotoxemia, and in fact 
did slightly worse than mice receiving resting macrophages (Figure 20A). The mice that 
received RM-IC had a 90% survival rate, regardless of whether the macrophages that 
were transferred were from WT or stat6 KO mice (Figure 20B). Thus, the ability to provide 
protection from lethal endotoxin challenge highlights a major functional difference 
between the R-M and IL-4-treated AA-M. 
3.4.9 Cytokine Expression Profile of Human Macrophages 
To extend our observations from mouse to human, we stimulated human monocyte 
derived macrophages from six different healthy human donors with the same conditions 
used for mouse BMDM and assessed the cytokine levels in the supernatants. The results 








Figure 20: Regulatory macrophages provide protection from lethal endotoxemia. (A) 
BALB/c mice received 1x106 resting non-stimulated macrophages (M filled circles) 
intraperitoneally or macrophages stimulated in vitro with LPS and 5µg of OVA opsonized 
with anti-OVA antibody (blue squares), 200 nM PGE2 (red squares), 200 μM adenosine 
(green squares) or 20 ng/ml IL-4 (yellow triangles), three hours prior to challenge with a 
lethal dose of endotoxin (10 mg/kg). The survival of the mice was recorded every eight 
hours over the next week. (B) A similar survival experiment was carried out in WT mice 
that received 1x106 LPS+IC macrophages from WT (blue squares) or stat6-/- (dark yellow 
squares) mice prior to endotoxin challenge. Each graph represents data of two independent 
experiments with 10 mice each experiment for each condition. The data from the control 







“reprogramming” stimulations when compared to their mouse counterparts. Whereas the 
RM-IC and RM-Ado show upregulation of IL-10, G-CSF was only signification in 
RM-IC. The other regulatory conditions did not show any observable differences 
compared to LPS stimulated macrophages (Figure 21A, 21B). The inhibition of LPS 
induced inflammatory cytokines IL-12/23p40 and TNF- was observed for RM-Ado and 
RM-PGE2 but not for RM-IC (Figure 21C, 21D). Interestingly, as observed with the 
mouse macrophages, the LPS induced production of IL-6 was significantly inhibited under 
all tested regulatory conditions in human macrophages (Figure 21E). The levels of IL-1 
were unaffected by the presence of any of the regulatory signals in human macrophage 
(Figure 21F). These results demonstrate that regulatory signals are inducible in human 
macrophages and when induced, they have distinct cytokine signatures that differentiate 
them from M1-M and AA-M. 
3.5 Discussion 
It has been suggested that there are many potential reprogramming signals that can 
change the phenotype of stimulated macrophages. In earlier reports, we demonstrated that 
macrophages stimulated with TLR ligands in the presence of high density immune 
complexes assumed immunoregulatory functions by dampening inflammatory cytokine 
production and turning on IL-10 secretion97,114. We know now that the induction of R-M 
required two concurrent signals; one to activate the transcription factors necessary for 
cytokine production and the second to “reprogram” the cell to secrete immunoregulatory 






Figure 21: Cytokine profiles of human macrophages under regulatory stimulation 
conditions. Human monocyte-derived macrophages were cultured at the concentration of 
5x105 cells/ 500 L of medium in the presence of M-CSF and were left unstimulated or 
stimulated with 10 ng/ml LPS (L), a combination of LPS and 5µg of OVA opsonized with 
anti-OVA antibody (L+I), 200 nM PGE2 (L+P), 200 μM adenosine (L+A), or 20 ng/ml IL-
4 for 24 hours. The levels of all indicated cytokines except IL-12/23p40 were measured 
using a bioplex assay (A-D, F). IL-12/23p40 levels were measured using a sandwich 
ELISA kit (E). The horizontal bar represents the mean value and the asterisks represent the 
significance of the observed values compared to LPS treated cells. Figure was generated 





were capable of inducing macrophages with an immunoregulatory functions. We 
demonstrated that all of these macrophages exhibit common characteristics, such as the 
production of high levels of immunomodulatory cytokines, including IL-10, and the 
secretion of reduced levels of inflammatory cytokines, such as IL-1, IL-6, and IL-12/23. 
This change in cytokine profile is important because it has a direct impact on how immune 
responses develop and on disease clearance. Additionally, these cells produced higher 
levels of transcripts for cell growth and angiogenic factors as determined by RNA-seq 
analysis. IPA analysis revealed that R-M are closely associated with cell growth and 
proliferation regardless of whether they were induced with immune complexes or 
adenosine. Thus, it is likely that all R-M contribute to the maintenance of homeostasis by 
dampening immune responses and promoting cellular repair. 
The classification of macrophages has become increasingly more complex and 
controversial. Although there is a reasonable consensus as to what constitutes M1-M, 
there remains a substantial degree of confusion regarding what constitutes the so-called 
M2-M. The original grouping of all macrophages that were not M1-M into the M2 
category was instructional because it fostered the idea that not all stimulated macrophages 
are the same. However, it has also led to the misconception that all M2-M are similar, and 
this does not appear to be the case. In this work, we demonstrate that R-M are quite 
distinct from IL-4 treated AA-M with respect to metabolism and disease modulation. We 
also demonstrate that macrophages with potent immunoregulatory activity can be 





macrophage populations has delayed attempts to deplete specific macrophage 
subpopulations or to target drugs to one subset or another.  
Previous work by the Mosser lab has demonstrated that Regulatory macrophages 
produce high levels of nitric oxide following stimulation44. This is in direct contrast to AA-
M that fail to produce nitric oxide upon activation. The failure of AA-M to produce nitric 
oxide has been attributed to their induction of Arginase-1, which converts arginine to 
ornithin44,48. Consequently, Arg-1 has been used as a biomarker to identify AA-M, and 
several groups have mistakenly identified AA-M in tissue based exclusively on their 
expression of Arg-1. It is now known that multiple macrophages populations can produce 
Arg-1 following activation61,87. While the use of Arg-1 as a biomarker remains 
controversial, the lack of nitric oxide by AA-M provides evidence that R-M and AA-
M display fundamental differences in their arginine metabolism.   
Other research groups have implicated metabolic reprogramming as an important 
factor in the polarization of macrophages into M1 and M2 phenotype115,116. It has been 
reported that metabolic pathways shift to anaerobic glycolysis in M1-M and to oxidative 
glucose metabolism in M2-M109. To determine if our macrophage populations showed 
differences in glucose metabolism, we utilized a glucose consumption and L-lactate 
production assays. We demonstrated that R-M undergo enhanced glycolysis and produce 
L-lactate similarly to M1-M. This observation may not be surprising since both M1 and 
R-M are stimulated with LPS, but it does reveal that the reprogramming signals that so 





M show minimal increases in glucose consumption and low levels of L-lactate 
production. These cells showed more metabolic similarities with the non-stimulated cells, 
than they did with the R-M. Our IPA analyses of metabolic pathways in R-M confirm 
that these macrophages resemble M1-M and are clearly distinct from AA-M. The 
differences associated with metabolism are just one example that helps to disprove the 
belief that all non-M1-M are M2-M.  
 The immunomodulatory effects of IL-10 appear to be most pronounced at the level 
of antigen presenting cells. Therefore, the high levels of IL-10 production from R-M 
suggests that macrophages themselves are the main regulators of macrophage activation, 
and that this is a primary function of R-M. Interleukin-10 has been previously shown to 
inhibit IFN- and TNF-α production and offer protection during experimental 
endotoxemia112,117,118. Hence, we hypothesized that the R-M would confer protection in 
experimental sepsis models in mice. The administration of R-M increased the survival of 
mice during endotoxemia, whereas the addition of AA-M did not. In our experiments, the 
addition of IL-4 treated macrophages actually increased mortality. This experiment 
provided evidence that the generation of R-M and AA-M in disease can have a polarize 
effect on the outcome of disease. Additionally, this supports the idea that the selective 
depletion of a single macrophage population can have a direct effect on disease 
progression. It has previously been shown that IL-4 treatment of macrophages can augment 
their production of IL-12119,120 and this observation may explain why IL-4 treated 





endotoxin shock has not been clearly defined. However, in a S. aureus triggered sepsis and 
an arthritis model, the survival of il-4 deficient mice was dependent on the genetic 
background of the mice121. The results from our studies clearly demonstrate that R-M and 
AA-M have different functions, reaffirming that these macrophages should not be 
considered part of the same class.  
To address whether IL-4 or STAT6 signaling was a requisite for regulatory 
macrophage functions, we studied cytokine production from macrophages from stat6-/- 
mice stimulated under immunoregulatory conditions. Signaling through STAT6 was 
previously demonstrated to be important for the anti-inflammatory properties of IL-457,122 
and for the generation of AA-M.122. In our hands, macrophages from stat6 deficient mice 
failed to induce ym1 and relmα expression as previously reported122. The stat6 deficient 
macrophages retained their ability to induction of anti-inflammatory IL-10 and the down 
regulation of pro-inflammatory IL-12, IL-1 and IL-6 following regulatory activation. 
Additionally, stat6 deficient macrophages that were stimulated with immune complexes 
were capable of protecting mice from lethal endotoxin challenge. From this, we concluded 
that STAT6 signaling was dispensable for the generation of R-M. The fact that regulatory 
activation is independence from STAT6 signaling has demonstrate that there is no overlap 
with the pathways required for alternative activation. This supports the idea that the 
classification of R-M and AA-M as subset of M2-M is both inaccurate and misleading.  
It is our belief that a transcriptomic analysis would be the most appropriate way of 





and mouse124 macrophage subsets has been previously reported and have helped to 
highlight the differences in activated macrophage. Through PCA and heat map analysis we 
demonstrated that Regulatory macrophages and Alternatively Activated macrophages are 
characterized by very different transcriptomes. While the Regulatory macrophages cluster 
with the LPS treated macrophages, the Alternatively Activated macrophages clustered with 
non-stimulated cells. Additionally, our analysis revealed that AA-M were predicted to be 
involved in cell differentiation and elongation, whereas R-M were predicted to promote 
cell growth, angiogenesis, and repair. This shows that Regulatory and Alternatively 
Activated macrophages are not only different in the number of genes that they induce, but 
in their overall functionality.  
The generation of transcriptomic profiles allowed us to identify every gene 
response for the observed activation phenotypes. We compiled a list of genes that was 
associated with Alternatively Activated macrophages and began to realize that most of 
these genes were absent from the Regulatory macrophage profiles. Most of the genes that 
we report to be specifically upregulated in AA-M agree with previously published 
reports124. To further our analysis we identified the transcripts produced by R-M that were 
absent in AA-M. This approach was undertaken to identify a “core transcriptome” that 
would define macrophages with an immunoregulatory phenotype. We identified some 182 
genes that were uniquely upregulated in R-M, relative to other macrophage populations, 
including resting, M1, and AA-M. We believe that these genes are responsible for the 





it will be possible to better understand how these macrophages function. In addition to 
examining differences in the transcripts produced by AA-M relative to R-M, our analysis 
also examined similarities among transcripts produced by the different R-M populations. 
This helped us realize that while Regulatory macrophages can be transcriptomically 
different from one another, they share a set of core genes that is responsible for their 
immunoregulatory functions. 
The plasticity of macrophages have made it difficult to study this cells in tissue. 
We recently demonstrated that M1-M gradually transition into R-M following 
stimulation61, and this transition makes it difficult to establish a baseline biomarker 
expression level from which to compare. Furthermore, the “reprogramming” signals that 
induce R-M affect the chromatin associated with regulatory transcripts67,77, making it 
difficult to use promoter-reporter mice. Recently, our attempts to utilize il-33 reporter mice 
as an indicator of regulatory activation failed125. We assume that the epigenetic 
modifications that lead to transcript expression in R-M are not preserved in these reporter 
mice. The need for reliable protein biomarkers for R-M remains of the utmost importance. 
This work identified that the chemokine receptor CCR1 was upregulated at both the mRNA 
and protein levels in R-M, and this upregulation occurred independent of STAT6 
expression. Thus CCR1 represents a potential biomarker for R-M. Attempts to identify 
R-M in tissue based on CCR1 expression are underway. This chemokine receptor has 





models126,127. How this receptor affects the migratory pattern of R-M is of future interest 
to us. 
In conclusion, this study has demonstrated that R-M are distinct from AA-M. In 
fact, R-M are transcriptionally more closely related to M1-M, but they distinguish 
themselves from the latter by a relatively small and unique set of transcripts and immune 
regulatory functions. Although there are subtle differences in the gene expression patterns 
and cytokine/chemokine responses among the differently generated Regulatory 
macrophage, it should be appreciated that these macrophages are biochemically and 
functionally related, and distinct from M1-M and AA-M. Hence we recommend 
considering Regulatory macrophages as a separate macrophage population, and not as a 





Chapter 4: Conclusions  
 The research conducted in this dissertation has helped us to gain a better 
understanding of the Regulatory macrophage. We have demonstrated that Regulatory 
macrophages can be generated by simultaneously adding a TLR ligand and a secondary 
reprogramming signal such as immune complexes, adenosine or prostaglandin E2. The 
addition of these secondary signals causes a dampening of the pro-inflammatory cytokines 
IL-12, IL-1 and IL-6, while inducing the production of anti-inflammatory IL-10. This 
immunoregulatory phenotype observed in macrophages can be attributed to a group of core 
immunoregulatory genes that is shared between the regulatory conditions. These 
immunoregulatory genes are not limited to, but include il-33, flrt3, and ccr1, since these 
genes were found to be strongly induced in response to regulatory inducers, but failed to 
be induced with LPS or IL-4 treatments. Additional studies on CCR1 surface expression 
confirmed that increases in this chemokine receptor can be associated with regulatory 
activation. While the plasticity and auto-regulatory mechanisms associated with 
macrophages have made studying their activation states difficult, we believe that we have 
found a stable surface marker that can be used for characterization. Although more than 
one marker will be required to accurately describe a macrophages activation state, the 
expression of CCR1 has provides a new marker for identification of macrophages with 
immunoregulatory activity.  
 This work also provided evidence that Regulatory macrophages and Alternatively 





dampening of pro-inflammatory cytokines was associated with regulatory activation, while 
alternative activation produced little to no detective cytokines. Regulatory macrophages 
showed increased glucose consumption and L-lactate production upon activation, which 
was similar to the M1 macrophages that had been stimulated with LPS alone. The 
Alternatively Activated macrophages showed only a slight increase in metabolism and 
remained similar to non-stimulated cells. The induction of immunoregulatory genes in 
Regulatory macrophages was shown to be independent of STAT6 signaling. Conversely, 
the genes associated with alternative activation were found to be dependent on STAT6 
signaling and failed to be induced in the absence of STAT6. Finally, the Regulatory 
macrophages provided protection against lethal endotoxin challenge, while Alternatively 
Activated macrophages exacerbated the onset of disease symptoms leading to increased 
mortality. The fact that Alternatively Activated macrophages and Regulatory macrophages 
lack common markers, arise from vastly different stimuli, and behave differently in 
endotoxin challenge model, help to supports the idea that these cells were wrongly 
classified together as a subset of M2 macrophages. This dissertation suggests that a new 






Chapter 5: Future Directions 
Continued Studies at the DNA Level  
 Further studies are underway in the Mosser lab on Regulatory macrophages. 
Promoter analyses are being conducted to identify transcription factor binding sites 
associated with genes that are induced or repressed following regulatory activation. The 
expression data from the RNA-seq analysis in combination with known promoter 
sequences will help to identify transcription factors associated with immunoregulatory 
genes. Identification of these binding sites will enable a genome wide search for genes with 
these promoter characteristics. The RNA-seq analyses identified mRNA transcripts of 
genes with unknown functions. This predicted gene set might contain important 
components of the immune regulation response. The over expression of these genes or their 
knockdown with siRNA can be used to ascertain the function of these yet to be 
characterized proteins. This may lead to the discovery of important regulators of the 
immune response. Additionally, the overexpression of il-33, flrt3, and ccr1 could be 
examined in inflammatory disease models to determine if their expression level has a direct 
effect on the immunoregulatory activity of Regulatory macrophages.  
Continued Studies at the RNA Level 
The RNA-seq analysis for this study was carried out at single time point, i.e 4 hours 
after stimulation. By expanding the time points in our RNA-seq analysis it may be possible 





plasticity of macrophages and the strength of activation signals cannot be overlooked. 
Hence to understand long term effects of these stimulations, transcriptomic profiles should 
be generated at multiple time points. Similarly, the addition of regulatory inducers at 
suboptimum concentrations can reduce the production of pro-inflammatory cytokines, but 
fail to induce anti-inflammatory cytokines. The addition of a time component and signal 
strength component would suggest that a three dimensional transcriptomic model might be 
the most accurate way of quantifying macrophage activation. The development of a three 
dimensional model would benefit researchers in several ways. First, it would allow 
researchers to more accurately characterize macrophages that have been isolated at 
different stages of disease progression. This would reflect how long the macrophage had 
been stimulated and the relative concentration of stimuli in the environment. Second, a 
model of this nature could be adapted to reflect cells that had undergone multiple 
stimulation events. Finally, a model of this nature would easily be able to accommodate 
newly described activation states. The development of a detailed three dimensional model 
will take years of transcriptomic analysis, but a model of this nature might be required if 
we hope to fully understand macrophage activation. 
It is important to point out that there are several experiments that would 
immediately increase our understanding of macrophage activation. First, only about twenty 
of the immunoregulatory genes have been validated through qRT-PCR in this study. The 
other potential candidate genes identified in our primary analysis are to be screened as 
biomarkers for Regulatory macrophages. Second, performing RNA-seq analysis on 





“core regulatory genes”. This has the potential to identify the gene responsible for the 
immunoregulatory phenotype. Third, using qRT-PCR to validate the genes uniquely 
expressed in the individual regulatory condition. These genes may allow macrophages to 
generate stimulation-specific responses required for the elimination of diverse pathogens. 
Studying them will allow us to better understand the subtle differences among R-M. 
Finally, the development of a customized Nanostring platform would aid researchers in 
identifying a macrophage’s activation state. This would provide a quick and cost effective 
method for understanding how macrophages are effecting tissue microenvironments. This 
may provide important clues to understanding how macrophage activation affects disease 
progression and resolution. These four experiments are currently underway and should 
yield results in the near future. 
Continued Studies at the Protein Level 
 While the measurement of RNA concentration is great for early activation time 
points, the short period of time required for gene transcription can limit the window for 
detection. Additionally, variations in RNA stability and translational regulation can affect 
the observed protein levels. Therefore the identified mRNA markers are currently being 
validated at the protein expression level to identify suitable markers for murine R-M. 
Members of the Mosser lab are working to perform proteomic analysis on human 
macrophages exposed to different activation conditions. This is in an attempt to identify 
protein biomarkers and to identify proteins with functional significance. The identification 





macrophage biology and therapeutics. In cases of cancer, the anti-inflammatory and 
angiogenic nature of Regulatory macrophages could result in increased tumor growth. The 
selective depletion of this immunoregulatory macrophages could allow Classically 
Activated macrophage to product the pro-inflammatory environment needed for tumor 
destruction. Conversely, the removal of Classically Activated macrophages in cases of 
autoimmunity or autoinflammatory diseases would make it easier for Regulatory 
macrophages to limit inflammation and alleviate disease symptoms. The manipulation of 
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